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ABSTRACT 
Dioxygenase enzymes such as the HIF hydroxylases (PHD1-3, FIH) and the Ten-eleven 
translocation (TET1-3) enzymes regulate the activity of the hypoxia inducible factor-1 (HIF-
1) transcription factor and the DNA methylation status of cells, respectively. Aberrant 
accumulation and activation of HIF-1 can allow malignant cells to acquire attributes that 
promote progression, chemotherapy resistance, and survival, while aberrant hypermethylation of 
gene promoters can silence the expression of tumor suppressor genes essential to preventing 
tumorigenesis. Inadequate levels of intracellular ascorbic acid (AA), a necessary cofactor for 
optimal dioxygenase enzyme function, could potentiate these tumorigenic conditions. In fact, 
plasma levels of AA have been found to be below normal physiological levels in individuals 
with melanoma, as well as other cancer types. Interestingly, melanoma tumors frequently 
demonstrate both high expression of HIF-1 and increased promoter methylation. AA therefore 
may present a valuable adjuvant therapy option for melanoma patients by regulating the HIF-1 
and DNA demethylation pathways. In these studies, we investigated the ability of AA 
supplementation to decrease aberrant HIF-1 accumulation and activity in melanoma cell lines 
and to increase global 5-hydroxymethylcytosine (5hmC) content of DNA in metastatic 
melanoma to ultimately reduce the malignant potential. Our studies showed that treatment with 
AA (reduced vitamin C) significantly increased intracellular vitamin C content of cultured 
melanoma cells and significantly decreased the stability, accumulation, and transcriptional 
activity of HIF-1α. Supplementation with AA also significantly increased global 5hmC content 
and ultimately resulted in the significant decrease of malignant potential of metastatic melanoma 
cells. Additionally, we discovered novel evidence that HIF-1α may regulate the DNA 
methylation status of melanoma cells by influencing the expression of TET2. Taken together, 
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these results suggest that deficiencies in AA levels, commonly observed in malignant tissue and 
blood plasma of cancer patients, may be a contributing factor to the deregulation of the HIF-1α 
and DNA demethylation pathways. Deregulation of these pathways is likely due to the loss of its 
cofactor function for the dioxygenase enzymes that tightly regulate various oncogenic factors. 
Furthermore, AA has the potential to be a powerful adjuvant therapy for metastatic melanoma, 
and further investigations in multiple cancer types are warranted to advance the use of AA to the 
clinical setting.  
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CHAPTER 1 
INTRODUCTION 
 
Ascorbic acid (AA; reduced vitamin C) is a well-known water soluble anti-oxidant and a 
key nutrient that is necessary for most life on the planet. AA is a simple six carbon molecule 
closely related to glucose. AA was first isolated in the late 1920’s and early 1930’s by a 
Hungarian scientist named Albert von Szent-Györgyi, who later won the Nobel prize in 
physiology or medicine in 1937, in part because of his discovery. A high physiological 
concentration of ascorbic acid has long been considered an indicator of good health. Currently, 
there is mounting evidence that ascorbic acid may be useful for treating or preventing multiple 
medical conditions including cardiovascular disease, diabetes, Alzheimer's disease, and 
especially cancer (Bowman, 2012; Gokce et al., 1999; Harding et al., 2008). While AA therapy 
may likely be useful in treating a variety of different malignancies, it may well be most 
advantageous for treating melanoma. 
Melanoma is a malignancy derived from melanocytes in the epidermis and is responsible 
for 75 % of skin cancer fatalities (Siegel, Miller, and Jemal, 2016). Once identified, primary 
melanomas can be easily cured by surgical excision; however, patients with metastatic disease 
have few treatment options, generally resulting in a poor prognosis. Thus, evaluation of the anti-
malignant properties of AA as an adjuvant therapy against melanoma is of timely importance. 
In this work, we explore and investigate the effect of AA on human melanoma cells via 
its often-overlooked enzymatic cofactor function. The results of these studies provide evidence 
that supplementation with fully reduced vitamin C (AA) can decrease the malignant potential of 
metastatic melanoma cells, likely by inhibiting the aberrant protein accumulation of Hypoxia 
inducible factor-1α (HIF-1α) and increasing 5-hydroxymethylcytosine (5hmC) content of the 
DNA.  
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Mammalian synthesis of ascorbic acid 
All known plant species synthesize and accumulate ascorbic acid, albeit some species use 
different mechanisms to do so. Plant species that are able to accumulate high concentrations of 
AA are consumed as a dietary source of vitamin C by numerous animal species; however, most 
vertebrates also have the ability to endogenously synthesize their own AA. AA is synthesized in 
a multi-step enzymatic process from glucose, where the terminal reaction is the conversion of L-
gulono-1,4-lactone to L-ascorbic acid by the enzyme L-gulonolactone oxidase (GULO) (Fig. 1) 
(Linster and Van Schaftingen, 2007).  
 
Figure 1.  Mammalian synthesis of ascorbic acid. 
In mammals, ascorbic acid is synthesized in a multiple step enzymatic process within the liver. 
In the final reaction, the enzyme L-gulonolactone oxidase catalyzes the conversion of L-gulono-
1,4-lactone to L-ascorbic acid. In addition, the intermediate L-gulonate can be shunted into the 
pentose pathway. 
 
 
Mammals synthesize AA in the liver, whereas lower vertebrates such as fish, amphibians, 
and reptiles do so in the kidneys (Linster and Van Schaftingen, 2007). While the ability to 
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synthesize AA has been highly conserved throughout the animal kingdom, several bat species, 
guinea pigs, and anthropoid primates (including humans) are unable to endogenously synthesize 
AA (Drouin, Godin, and Pagé, 2011; Linster and Van Schaftingen, 2007). The inability to 
synthesize AA is caused by severe mutations to the GULO gene. In humans, seven out of twelve 
exons are deleted, resulting in the transcription and translation of a non-functional protein 
(Drouin et al., 2011). Although bats, guinea pigs, and anthropoid primates have this trait in 
common, evidence suggests there is not a single common ancestor where loss of GULO evolved 
linking these mammalian species together. Using a combination of phylogenetics and 
evolutionary biology, researchers have determined that the loss of AA synthesis has occurred at 
least three distinct times during mammalian evolution, with primates and guinea pigs developing 
this trait approximately 61 million and 14 million years ago, respectively, while bats are yet to be 
determined (Fig. 2) (Drouin et al., 2011).  
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Permission granted to reproduce figure from copyright holder © (Drouin et al., 2011) 
 
Figure 2. Phylogenetic distribution of the ability to synthesize vitamin C in mammals. 
Lineages able to synthesize vitamin C are in black; those incapable are in gray. The phylogenetic 
relationships are based on those in reference (Prasad, Allard, and Green, 2008). 
 
Loss of ascorbic acid synthesis may have provided a selective survival advantage for these 
species, possibly by inhibiting the production of H2O2, a known byproduct of GULO activity 
(Linster and Van Schaftingen, 2007). This may have been beneficial by limiting free radical 
induced DNA damage. Another plausible benefit from the loss of AA synthesis may have been 
the conservation of glucose or the accumulation of AA intermediates that could be shunted into 
other metabolic pathways such as the pentose synthesis pathway. These benefits may have been 
particularly advantageous given that all species that lost GULO function had diets that were 
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naturally rich in vitamin C, thus losing AA synthesis was not detrimental to survival. However at 
least two bat species within two different families of Chiroptera have been found to reactivate 
GULO activity, although it was several fold lower than that found in mice (Drouin et al., 2011). 
This finding has prompted some researchers to hypothesize loss of GULO did not encourage 
survival but instead was a physiologically insignificant mutation that has been preserved over 
time.  
Transport of vitamin C in humans 
 Non-AA synthesizing animals have developed intricate systems for maintaining 
consistent steady-state AA levels through intestinal absorption, dissemination, recycling, and 
excretion. Dietary vitamin C1 exists in two forms, as ascorbic acid (AA; reduced vitamin C) or a 
fully oxidized form called dehydroascorbic acid (DHA). Both forms of vitamin C are absorbed 
by the brush border membrane within the lumen of the small intestine, albeit AA absorption in 
humans is greatest in the distal ileum, while maximum DHA absorption occurs in the jejunal 
segments (Malo and Wilson, 2000). Differences in regional vitamin C absorption are likely due 
to the distribution of vitamin C transporters within the intestine. AA is specifically transported 
across the plasma membrane by sodium dependent vitamin C cotransporters (SVCT1 and 2), 
while DHA competes with glucose to enter cells through glucose transporters (GLUTs) (Du, 
Cullen, and Buettner, 2012b). 
 The SVCT1 isoform is primarily responsible for AA absorption and reabsorption from 
the intestinal lumen and kidneys, and is confined to the apical surface of enterocytes and renal 
tubule cells (Du et al., 2012b; Lindblad, Tveden-Nyborg, and Lykkesfeldt, 2013). Transport of 
AA is dependent on a sodium gradient where two moles of sodium enter the cell per every mole 
of AA (Wohlrab, Phillips, and Dachs, 2017). Alternatively, DHA enters the apical side of 
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enterocytes via GLUT1 and 3. Intestinal uptake of DHA via GLUT transport has a lower 
efficiency (Km = 0.8 mM) compared to AA uptake by intestinal SVCT1 transporters (Km = 0.2 
mM), however maximal uptake rates between the two systems are similar in the absence of 
glucose (Du et al., 2012b; Wilson, 2002). 
Once DHA enters the enterocytes, it is enzymatically reduced to AA in the cytosol either 
by glutathione-dependent or nicotinamide adenine dinucleotide (NADPH)-dependent DHA 
reductases (Lindblad et al., 2013; Linster and Van Schaftingen, 2007). Additionally, cytosolic 
glutathione can spontaneously reduce DHA. However, this reaction is not thermodynamically 
favored, and thus is thought to contribute little to DHA reduction (Linster and Van Schaftingen, 
2007). Accumulated AA in the intestinal epithelium is released into the plasma by diffusion or 
hypothesized volume sensitive anion channels, allowing systemic dissemination of vitamin C in 
the form of AA (Lindblad et al., 2013; Wilson, 2002). Circulating levels of DHA are very low (2 
– 5 µM) compared to levels of AA (40 – 80 µM) (Du et al., 2012b; Liang, Johnson, and Jarvis, 
2001). Low intra-enterocyte and plasma concentrations of DHA help promote continual DHA 
uptake from the intestinal lumen down its concentration gradient.  
 The expression of the SVCT2 isoform is wide-spread throughout most tissues, allowing 
this transporter to maintain systemic organ and tissue levels of AA (Fig. 3) (Corti, Casini, and 
Pompella, 2010; Lindblad et al., 2013). While SVCT1 and 2 share approximately 65 % amino 
acid identity (Lindblad et al., 2013), SVCT2 ( Km ≈ 8 – 62 µM) has a higher efficiency for AA 
uptake than SVCT1 (Km ≈ 65 – 240 µM) allowing tissues to accumulate a higher level of 
intracellular AA than is found in the plasma (Du et al., 2012b). Some tissues, such as muscle and 
cardiac tissue, accumulate relatively low concentrations of AA (0.2 mM), while the brain 
accumulates the highest concentration of AA at approximately 2 – 10 mM (Lindblad et al., 
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2013). These levels are achieved even though SVCT2 is absent in the blood brain barrier. 
Instead, AA enters the brain by SVCT2 mediated transport into the cerebrospinal fluid at the 
choroid plexus (Lindblad et al., 2013). 
 
Figure 3.  A schematic diagram of the entry and recycling of ascorbic acid and DHA in the 
cell. 
Ascorbic acid enters the cell through sodium-dependent vitamin C co-transporters (SVCTs). 
Alternately, dehydroascorbate (DHA) competes with glucose (Glu) to enter the cell via the 
glucose transporters (GLUTs). Once inside the cell, DHA can be enzymatically or non-
enzymatically reduced in the cytosol to AA, promoting the accumulation of intracellular AA. 
 
Metabolism and maintenance of vitamin C 
 Once AA accumulates in the cytosol it can be used either as an anti-oxidant or an enzyme 
cofactor by donating an electron to a free radical or enzyme. In the process, AA becomes 
oxidized to form DHA. DHA itself has no biological activity because it is already fully oxidized. 
To preserve vitamin C activity, tissues can reduce DHA back to AA, a process called vitamin C 
8 
 
recycling, using the same enzymatic and non-enzymatic mechanisms present in the enterocytes. 
Vitamin C recycling also contributes to high AA accumulation within the cytosol; however, in 
some cases recycling of intracellular DHA may not be possible. Low activity of DHA reductases 
and/or depletion of glutathione and NADPH can inhibit the reduction of DHA to AA. Moreover, 
DHA is relatively unstable at physiological pH, resulting in its spontaneous and irreversible 
degradation to 2,3-diketogulonic acid (2,3-DKG), which can be sequentially metabolized into 
terminal end products of L-erythrulose and oxalic acid (Linster and Van Schaftingen, 2007). 
Metabolites of DHA are exported into the plasma where they are filtered and excreted by the 
kidneys. Thus, intracellular reduction of DHA to AA serves to not only provide functional AA, 
but also to prevent DHA degradation and loss of total vitamin C.  
 As previously stated (Du et al., 2012b), normal physiological levels of plasma AA levels 
range from approximately 40 – 80 µM, but this range is highly variable depending on several 
factors including age, sex, medical conditions, and the socioeconomic status of an individual. 
Nonetheless, the body takes great measures to maintain a constant steady-state of AA. Dietary 
vitamin C absorption becomes saturated as plasma AA levels approach the upper physiological 
limits (Lindblad et al., 2013). Excessive circulating levels of AA are filtered by the kidneys and 
excreted in the urine, as AA is highly water soluble. Conversely, during periods of mild to 
moderate deficiency, AA is reabsorbed in the tubular system (Corti et al., 2010). Plasma contains 
low circulating levels of DHA, primarily because of its minimal release from intestinal 
epithelium and its instability (Lindblad et al., 2013; Linster and Van Schaftingen, 2007; Wilson, 
2002). In addition, intracellular loss of DHA from somatic cells through GLUTs and oxidant 
dependent oxidation of AA in the plasma can elevate circulating DHA levels causing the risk of 
vitamin C loss. However, vitamin C loss is minimized via DHA uptake by erythrocytes. 
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Erythrocytes lack both SVCT1 and 2 transporters, but are adept at rapid DHA uptake from 
GLUT1 (Du et al., 2012b; Lindblad et al., 2013). Once recycled and accumulated as AA, the AA 
in erythrocytes is slowly released, presumably by diffusion, back into the plasma (Mendiratta, 
Qu, and May, 1998), preserving functional AA.  
Vitamin C deficiency and disease  
 Although non-AA synthesizing animals are proficient at maintaining vitamin C 
homeostasis, lack of vitamin C consumption for prolonged periods of time results in a medical 
condition known as scurvy. Scurvy is a potentially fatal condition characterized by chronic 
fatigue, joint pain, gum bleeding, poor wound healing, and internal hemorrhaging. Scurvy was 
commonly associated with transoceanic European sailors from the 15th through 18th centuries and 
is estimated to have killed nearly two million men during that time (Carpenter, 1986; Hemilä, 
2006). Today, a diagnosis of scurvy is rare in industrialized countries; however, it is more 
prevalent in individuals living below the poverty line and in third world countries (Institute of 
Medicine, 2000). Death from scurvy is typically due to exsanguination from massive internal 
bleeding occurring after weeks of AA depletion, yet scurvy can be reversed, with a full recovery, 
by vitamin C consumption, even when death is imminent. The severity of the symptoms of 
scurvy, culminating in death, highlights the critical importance of vitamin C in human 
physiology. In fact, the term “vitamin C” was given to AA to indicate it is essential for human 
survival, while the same molecule technically is not a vitamin for AA-synthesizing animals.  
Unfortunately, some chronic medical diseases, such as cancer, are now thought to play a 
role in nutrient depletion such as vitamin C. In 1952 Oscar Bodansky M.D. performed one of the 
first studies documenting significantly lower plasma AA levels in cancer patients compared to 
healthy individuals (Bodansky, Wroblewski, and Markardt, 1952). Evaluation of AA levels in 
10 
 
cancer patients continued into the next decade (Fraenkel-Conrat, Stoy, and Tsai, 1967), 
prompting some of the first clinical trials of AA supplementation therapy for patients with 
advanced cancer by Cameron and Pauling (Cameron and Campbell, 1974; Cameron and Pauling, 
1976). In these trials, Cameron and Pauling reported that high dose infusion of I.V. AA extended 
the life of patients by approximately 160 days compared to those without treatment. Almost 
immediately contradictory results were published (Creagan et al., 1979), embroiling vitamin C 
cancer therapy into controversy that still exists today. Modern clinical trials still investigate the 
use of high dose AA therapy on cancer patients with mostly mixed or inconclusive results. The 
rationale for such a treatment is that intravenous administration of high dose AA can bypass the 
strict regulation of the gut and increase peak plasma AA levels to approximately 500 times 
typical physiological levels (Stephenson, Levin, Spector, and Lis, 2013). At these concentrations 
AA acts as a pro-oxidant facilitating the formation of H2O2. Excessive H2O2 has been observed 
to be selectively cytotoxic to malignant cells in vitro and in vivo models (Chen et al., 2005; Chen 
et al., 2007; Ohno, Ohno, Suzuki, Soma, and Inoue, 2009), presumably because glutathione 
depleted malignant cells, likely from an elevated endogenous oxidative burden or decreased 
synthesis of endogenous antioxidant enzymes, cannot tolerate the added oxidative stress of H2O2. 
While the efficacy of high dose AA therapy continues to be debated, it is generally accepted that 
it is not uncommon for individuals with cancer to have below normal levels of plasma AA. In 
some instances, oncology patients can become vitamin C deficient to the point of developing 
scurvy. Case reports from the Jean Verdier Hospital in France during the mid-1990’s indicated 
that 3 % of their cancer patients were concurrently diagnosed with scurvy, approximately 15 
times higher than the scurvy diagnosis of non-cancer patients (0.2 %) (Fain, Mathieu, and 
Thomas, 1998). Conclusive evidence on the mechanism of AA depletion in cancer patients is yet 
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to be elucidated. Some have postulated that chemotherapy and radiation treatments as well as the 
associated emesis contribute to or causes the observed AA deficiency in these patients. However 
a study by Campbell et al. found that GULO -/- knockout mice inoculated with B16 murine 
melanoma and Lewis Lung Carcinoma had significantly lower plasma and liver tissue AA levels 
(determined after tumor volume reached 1000 mm3) compared to non-inoculated mice, even 
though they were supplemented with an identical concentration of AA (Campbell et al., 2014). 
This evidence suggests an active malignancy, and not chemotherapy induced malnutrition, may 
be responsible for AA depletion observed in cancer patients. Regardless of the mechanism, even 
moderate AA deficiency may significantly increase the risk of cancer mortality. In a study, 
individuals with a plasma AA concentration < 28 µM had a 62 % increased likelihood of dying 
from cancer compared to those with AA levels ≥ 74 µM (Loria, Klag, Caulfield, and Whelton, 
2000). Moreover, that risk decreased dose-dependently with increasing plasma AA (Goyal, 
Terry, and Siegel, 2013).  
The onset of scurvy following the depletion of vitamin C in non-AA synthesizing animals 
is not caused by the loss of an anti-oxidant, as there are many anti-oxidant enzymes, vitamins, 
and minerals found within the body. Instead these effects are caused by the inhibition of Fe II/2-
oxoglutarate (2-OG) dependent dioxygenase enzymes that requires AA as a cofactor (Kuiper and 
Vissers, 2014c). 2-OG dioxygenases regulate a vast number of cellular processes ranging from 
neurotransmitter synthesis to DNA modifications via the hydroxylation of different substrates. 
Individual subfamilies of enzymes are categorized either by the substrates they modify or the 
functions they regulate. Interestingly, aberrant function of several enzyme subfamilies may be 
related to malignant transformation or progression (Kuiper and Vissers, 2014c). 2-OG 
dioxygenases regulate processes significant to oncogenesis such as the activation of oncogenic 
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transcription factors, epigenetic modifications to DNA and histones, and changes in metabolism 
(Kuiper and Vissers, 2014c). Given the need for adequate AA to function as a cofactor and the 
observed AA deficiency of cancer patients, it is highly plausible that low levels of AA can 
contribute to aberrant regulation of cancer promoting pathways by the inhibition of 2-OG 
dioxygenases.  
Ascorbic acid is a cofactor for Fe II/2-oxoglutarate dioxygenases 
 2-OG dioxygenases likely contributed to the evolutionary history of life as we know it 
today. Many examples of 2-OG dioxygenases can be found in both bacteria and eukaryotes 
including fungi, plants, and vertebrates (Farrow and Facchini, 2014). In humans, 2-OG 
dioxygenases modulate the structure, function and/or activity of cellular substrates via 
hydroxylation. All 2-OG dioxygenases contain a conserved catalytic core that is comprised of a 
distorted double-stranded β-helix fold (DSBH) (Hewitson, Granatino, Welford, Mcdonough, and 
Schofield, 2005; Mcdonough, Loenarz, Chowdhury, Clifton, and Schofield, 2010). The DSBH 
core consists of 8 anti-parallel β-strands that form a major and minor β-sheet (Clifton et al., 
2006; Mcdonough et al., 2010; Ozer and Bruick, 2007), the latter being supported by at least 2 
N-terminal helices (Aik et al., 2015). While the enzyme core is highly conserved, different 
structures surrounding the DSBH are thought to influence substrate recognition, lending to the 
high degree of substrate variability observed between subfamilies (Aik et al., 2015; Clifton et al., 
2006; Flashman and Schofield, 2007; Hausinger, 2004). Before substrate binding and 
hydroxylation can occur non-heme ferrous iron (Fe II) coordinates with a conserved HXD/E…H 
motif, often described as a facial triad, within the DSBH core (Aik, Mcdonough, Thalhammer, 
Chowdhury, and Schofield, 2012; Hegg and Que, 1997; Valegard et al., 1998; Zhang et al., 
2000). Adjacent to Fe II binding is the binding site for the molecule 2-oxoglutarate (2-OG), the 
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enzyme family namesake (Aik et al., 2012; Clifton et al., 2006; Hausinger, 2004; Mcdonough et 
al., 2010). Binding of 2-OG is necessary to allow the entry of the substrate into the catalytic core 
(Kuiper and Vissers, 2014c). Once inside the core, the substrate, more specifically the C―H 
bond to be oxidized, is held in close proximity to Fe II by hydrogen, hydrophobic, and 
electrostatic interactions (Aik et al., 2012). Molecular oxygen (O2) can then enter the core and 
coordinate with Fe II to induce oxidative decarboxylation of 2-OG producing succinate, CO2, 
and a highly reactive Fe IV oxo intermediate. Fe IV rapidly extracts hydrogen from the substrate, 
replaces it with a hydroxyl group, while concurrently being reduced to Fe II in the process, in 
conjunction with the release of products and a hydroxylated substrate (Aik et al., 2015). 
However during the process of oxidative decarboxylation electron transfer to Fe IV can become 
uncoupled, resulting in the formation of Fe III (Kuiper and Vissers, 2014c). Fe III antagonizes 
enzyme function prompting the loss of catalytic activity and an inability to modify substrates. To 
reestablish enzyme activity, 2-OG dioxygenases utilize intracellular AA to further reduce Fe III 
to Fe II, thus restoring catalytic activity (Kuiper and Vissers, 2014c). Interestingly, the 
interacting site for AA within the DSBH core is extraordinarily specific for the ene-diol structure 
of AA. Therefore, other antioxidant molecules are unable to position in proximity to efficiently 
donate an electron to Fe III (Flashman, Davies, Yeoh, and Schofield, 2010), making AA an 
essential co-factor for optimal 2-OG dioxygenase activity (Fig. 4). 
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Figure 4.  A schematic diagram of Fe II/2-oxoglutarate dioxygenases and the structural 
significance of AA. 
Fe II/2-oxoglutarate dioxygenases are able to hydroxylate a substrate using a common set of 
cofactors including 2-oxoglutarate (2-OG), molecular oxygen, and enzyme bound non-heme 
ferrous iron. During the process of hydroxylation, electron transfer to iron can become 
uncoupled resulting in the formation of Fe3+ and loss of enzymatic activity. AA enters into a 
binding cleft that is highly specific for the ene-diol structure of AA, and donates an electron to 
reduce Fe3+ to Fe2+ restoring enzymatic activity. 
 
Regulation of the HIF transcription factors by ascorbic acid 
Solid tumors are comprised of multiple malignant and non-malignant cell populations. As 
the expansive mass continues to grow, oxygen deprivation in localized areas becomes common 
and allows for regions of intratumoral hypoxia. Oxygen deprivation applies selective pressure 
that promotes the clonal selection and expansion of malignant populations that are best suited for 
adaptation, survival, and replication. Surviving cells frequently have a combination of activated 
oncogenes and impaired tumor suppressors that increase the overall malignancy of the cancer. 
Hypoxia contributes to adaptation and survival, and thus can augment malignancy by inducing 
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changes in gene expression. Hypoxic gene expression is mediated by the predominate 
accumulation of the hypoxia inducible factor-1 transcription factor (HIF-1) in epithelial cells and 
HIF-2 in endothelial cells. HIF-1α and 2α are heterodimeric transcription factors, where HIF-1α 
and 2α are the oxygen responsive subunits that mediate transcription factor stability and activity. 
Elevated expression of either HIF-1α or 2α has been extensively documented in numerous solid 
malignancies (Semenza, 2010). HIF is known to promote the acquisition of multiple cancer 
hallmarks, contributing to wide-spread chemotherapy resistance and ultimately decreased patient 
survival (Semenza, 2010). 
 Under physiological tissue oxygenation (non-hypoxic), HIF-1α is post-translationally 
modified on proline 402 and/or 564 within the oxygen dependent death domains (ODD) by HIF-
prolyl hydroxylases (PHD1-3), belonging to the 2-OG dioxygenase family. The hydroxylation of 
proline residues promotes HIF-1α to interact with the von Hippel-Lindau tumor suppressor 
protein (pVHL), facilitating polyubiquination and subsequent degradation by the 26S 
proteasome, thereby inhibiting hypoxia gene expression. Alternatively, another member of the 2-
OG dioxygenase family, Factor Inhibiting HIF (FIH), hydroxylates asparagine 803 within the C-
terminal transactivating domain (C-TAD), inhibiting the interaction of the transcription factor 
with CBP/p300 co-activator, blocking gene transcription (Schofield and Ratcliffe, 2005) (Fig. 5). 
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Figure 5.  Canonical regulation of the HIF-1α transcription factor under normoxic 
conditions. 
A) The protein stability of HIF-1α is regulated by PHD1-3. During normoxic conditions, PHD 
enzymes require 2-oxoglutarate (2-OG), O2, Fe
2+, and AA for optimal activity. At optimal 
activity, PHDs hydroxylate HIF-1α protein, allowing it to interact with pVHL. pVHL 
polyubiquinates the subunit, targeting it for proteasomal degradation and inhibiting dimerization 
with HIF-1β. B) Additionally, HIF-1 transcriptional activity can be regulated by FIH. Using the 
same cofactors, FIH hydroxylates the transactivating domain of HIF-1α, inhibiting interaction 
with CBP/p300 transcriptional co-activator and blocking HIF regulated gene expression.  
 
When O2 becomes limiting, as during tissue hypoxia, the catalytic activity of HIF hydroxylases, 
particularly PHDs, is lost allowing for the accumulation and activation of the complete 
transcription factor to elicit the cellular hypoxic response. 
 In addition to the canonical HIF pathway, HIF-1α can also aberrantly accumulate in 
malignant cells in an oxygen independent manner, which usually involves some mechanism of 
HIF hydroxylase dysfunction. Inactivating mutations of the HIF hydroxylases are rare; however, 
a PHD2 gene mutation has been observed in endometrial cancer (Jokilehto and Jaakkola, 2010). 
Other mutations of consequence are the oncogenic mutations of succinate dehydrogenase (SDH) 
and fumarate hydratase (FH). These enzymes are integral components of the TCA cycle; 
however, inhibiting mutations to either enzyme allows for the elevated cellular content of 
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succinate or fumarate, respectively. These metabolic intermediates competitively bind the 2-OG 
site on HIF hydroxylases, inhibiting their functionality similar to O2 deprivation. Individual SDH 
and FH mutations have been found to be sufficient to induce HIF-1α activation adequate to 
confer a clear survival advantage to malignant cells (Masson and Ratcliffe, 2014; Raimundo, 
Baysal, and Shadel, 2011). In fact, additional TCA cycle metabolites including oxaloacetate, 
malate, isocitrate, and citrate have been observed to differently inhibit PHD and FIH isoforms 
under various assay conditions (Koivunen et al., 2007; Masson and Ratcliffe, 2014); however, 
the relevance of this finding in a physiological condition is unclear. 
 Similar to HIF hydroxylase inhibition by TCA cycle intermediates, inadequate 
intracellular AA may also promote aberrant normoxic accumulation and activation of HIF-1α in 
malignant cells. Accumulation of HIF-1α protein, as well as tumor stage, has been found to 
correlate with low tissue levels of AA in endometrial and colorectal cancers (Kuiper et al., 
2014b; Kuiper, Molenaar, Currie, Robinson, Pearson, and Vissers, 2010), suggesting inadequate 
intracellular AA may contribute not only to aberrant HIF-1α activation but also to malignant 
progression. In vivo studies using GULO -/- mice (a model of human AA dependency) 
inoculated with murine melanoma cells demonstrate that AA supplementation can decrease 
tumor accumulation of HIF-1α (Campbell et al., 2014) and decrease tumor volume (Campbell et 
al., 2014; Cha et al., 2011; Cha et al., 2013). Furthermore, tumor ascorbate levels inversely 
correlated to the expression of HIF-1 target genes (Campbell et al., 2014), providing further 
support for the use of AA as an adjuvant cancer therapy. 
Ascorbic acid influences DNA methylation patterns via TET enzymes 
 DNA methylation is the most prevalent form of epigenetic modification and is 
responsible for regulating many cellular processes, including gene expression, X chromosome 
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inactivation, genomic imprinting, and the pluripotency of stem cells (Monfort and Wutz, 2013; 
Suzuki and Bird, 2008). Normally, DNA methylation is generated by the addition of a methyl 
group to the 5 position of cytosine by DNA methyltransferases (DNMTs), yielding 5-
methylcytosine (5mC) (Ooi, O'donnell, and Bestor, 2009). Methylation of cytosine within a gene 
promoter silences gene expression by inhibiting transcription. Typically, 5mC is present at the 
same position on both the sense and anti-sense DNA strands, preserving epigenetic regulation 
following DNA replication and mitosis (Ficz and Gribben, 2014; Rasmussen and Helin, 2016). 
The status of DNA methylation within the cell can be altered by the three isoforms of the ten-
eleven translocation (TET) enzyme. TET1-3 are members of the 2-OG dioxygenase family that 
catalyze the formation of 5-hydroxymethylcytosine (5hmC) from 5mC (Huang and Rao, 2014). 
5hmC is relatively stable and abundant within the genome and is known to interfere with the role 
of DNMT1/UHRF1 complex in maintaining DNA methylation following DNA replication (Ficz 
and Gribben, 2014; Huang and Rao, 2014; Rasmussen and Helin, 2016). In addition, 5hmC can 
be further oxidized by TETs to 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC), which are 
then excised and replaced with unaltered cytosine by the DNA repair enzyme thymine-DNA 
glycosylase (TDG) (He et al., 2011; Ito et al., 2011) (Fig. 6). 
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Figure 6.  The active methylation and demethylation of cytosine. 
Cytosine can be methylated to form 5mC by multiple DNMTs. TET enzymes can facilitate 
active demethylation by oxidizing 5mC to 5hmC. TET enzymes can then further oxidize 5hmC 
to 5fC and 5caC, where the latter two intermediates are substrates for the DNA repair enzyme 
TDG followed by base excision repair (BER), which removes and replaces the modified cytosine 
with an unmodified cytosine. 
 
 
Reduced function of TET enzymes either by mutation or deletion has been prominently 
observed in hematological malignancies. While TET1 and 3 are seldom altered, more than 700 
mutations in TET2 have been identified in leukemia patients with a frequency of 50 % and 20 % 
in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), respectively 
(Huang and Rao, 2014). While the prevalence of TET mutations/deletions in solid malignancies 
is much lower, reduced protein expression and/or enzyme inhibition has been observed in clear-
cell renal cell carcinoma, colorectal, gastric, prostate, liver, lung, and breast cancers, in addition 
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to glioblastoma and melanoma, suggesting TET enzymes act as tumor suppressors (Huang and 
Rao, 2014; Rasmussen and Helin, 2016). It has been speculated that TET dysfunction promotes 
malignant progression by silencing the expression of tumor suppressor genes because of the 
failure to demethylate gene promoters (Huang and Rao, 2014). Further evidence must be 
collected before TET mutations are considered a “driver” of oncogenesis; however, there is a 
strong correlation between the absence of 5hmC in cancer and tumor growth and metastasis 
(Chen et al., 2017; Hsu et al., 2012; Song et al., 2013). Given that earlier studies determined 
TET proteins are solely responsible for genome wide hydroxymethylation of cytosine (Ficz and 
Gribben, 2014; Koh et al., 2011), aberrant TET activity undoubtedly contributes to cancer 
progression. Like all other 2-OG dioxygenases, TET proteins use AA as a cofactor to maintain 
enzymatic activity (Monfort and Wutz, 2013). Reliance on AA means that inadequate 
intracellular ascorbate may hinder the catalytic function of TETs similar to oncogenic mutations, 
and therefore contribute to cancer progression by silencing tumor suppressors. Multiple in vitro 
studies have demonstrated vitamin C supplementation increases the prevalence of 5hmC while 
also facilitating DNA demethylation (Blaschke et al., 2013; Dickson, Gustafson, Young, 
Zuchner, and Wang, 2013; Minor, Court, Young, and Wang, 2013; Monfort and Wutz, 2013; 
Yin et al., 2013). In these studies, vitamin C activity was dependent on TET expression 
(Blaschke et al., 2013; Minor et al., 2013; Yin et al., 2013) and the function of SVCT2 (Dickson 
et al., 2013), an AA specific transporter, confirming the importance of AA in modulating TET 
activity. 
Melanoma as a model for AA therapy 
 Melanoma is the deadliest form of skin cancer and its incidence has continually risen 
over the past 30 years. Current projections estimate 1 in 28 men and 1 in 44 women in the United 
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States will be diagnosed with skin melanoma in their lifetime, resulting in nearly 10,000 fatalities 
in 2017 (Siegel, Miller, and Jemal, 2017). Aberrant activation of the mitogen-activated protein 
kinase (MAPK) pathway, caused by NRAS and BRAF mutations, have been described in 
approximately 90 % of melanomas (Strickland, Pal, Elmets, and Afaq, 2015), contributing to 
malignant growth, proliferation, and survival (Inamdar, Madhunapantula, and Robertson, 2010). 
Melanoma growth is commonly classified into one of three stages: radical growth phase (RGP), 
vertical growth phase (VGP), or metastatic phase (MET) (Table 1). While primary melanomas 
can be readily cured by surgical excision, once metastasized the disease is highly aggressive and 
difficult to treat. The use of immunotherapy such as Interleukin-2 (IL-2) and BRAF inhibitors 
has resulted in more favorable initial responses. Unfortunately, these therapies can be highly 
toxic and frequently lead to acquired resistance and poor clinical outcomes, highlighting the need 
for new treatment strategies against metastatic melanoma. 
Stage of Malignancy Characteristics Cell Lines 
Radical Growth Phase 
(RGP) 
Expansive growth confined to epidermis SbCl2 
Vertical Growth Phase 
(VGP) 
Growth has penetrated the dermis and/or 
subcutaneous tissue; malignant cells 
may be disseminating into circulation 
WM3211, WM1366 
Metastatic Phase 
(MET) 
Tumor growth at a secondary site WM9, WM239A 
Unknown 
Malignant cells isolated from an 
unspecified stage 
WM3248 
Non-malignant Non-cancerous primary melanocytes HEMnLP 
Table 1.  Growth phases of malignant melanoma. 
Classification and description of different human melanoma cell lines and primary melanocytes 
used in this study. Cell lines are classified as designated by Rockland Immunochemicals Inc. at 
time of publication. 
 
 As previously mentioned, it is not uncommon for individuals with cancer to have below 
normal levels of plasma AA. Melanoma is one of many cancer types that has been documented 
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to be correlated with AA deficiency (Schleich et al., 2013). Interestingly, advanced melanomas 
have been shown to contain high aberrant activity of the HIF-1α transcription factor as well as a 
significant lack of 5hmC content (Kuphal, Winklmeier, Warnecke, and Bosserhoff, 2010; Lian et 
al., 2012), both of which may be explained, to some extent, by impaired HIF hydroxylase and 
TET enzyme function due to inadequate levels of AA. In the present work, we investigate the 
ability of different forms of vitamin C to decrease the malignant properties of human melanoma, 
in part, by promoting optimal activity of the HIF hydroxylases and TET enzymes. In chapter 2, 
we examine the ability of AA and an ascorbate analog (ascorbate 2-phosphate; A2P) to decrease 
the aberrant normoxic and hypoxia-mimetic induced protein accumulation and transcriptional 
activity of HIF-1α. Here, we demonstrate that not only is A2P more effective than AA in 
regulating HIF-1α, it was also capable of inhibiting invasion and anchorage independent growth 
of WM9 metastatic melanoma cells compared to non-treated controls. 
A recent hypothesis has suggested that treating malignant cells or patients with DHA 
would be a more beneficial therapy than AA. The rationale for this idea is that since many 
aggressive malignancies overexpress GLUT transporters, this would allow for increased uptake 
of DHA across the plasma membrane of these cells and translate into a higher intracellular AA 
content following DHA recycling than direct supplementation with AA (Mccarty, 2013). 
Therefore, in chapter 3 we sought to test this hypothesis by surveying the ability of AA, A2P, 
and DHA to decrease the hypoxia-mimetic induced activity of HIF-1α in six melanoma cell lines 
and melanocytes (Table 1). Our studies suggest, AA, particularly in the form of A2P, is 
significantly more effective than DHA in not only decreasing the activity of HIF-1α but also 
inhibiting invasive potential as determined using a WM9 tumor spheroid invasion model. 
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In addition to investigating the impact of AA supplementation on HIF-1α, we also 
examined if AA could increase the DNA 5hmC content of metastatic melanoma cells by 
augmenting the activity of TET enzymes. If so, elevated 5hmC content may allow for DNA 
demethylation and reexpression of tumor suppressor genes. These changes would be particularly 
relevant and advantageous in melanoma since malignancies retaining high 5hmC levels correlate 
with lower tumor stage and increased patient survival (Lee, Murphy, and Lian, 2014). In chapter 
4 we demonstrate that we are able to significantly increase the 5hmC content of WM9 metastatic 
melanoma cells following supplementation with A2P, likely by augmenting the activity of TET2. 
Surprisingly, we found that gene silencing of HIF-1α increased both gene and protein expression 
of TET2. Furthermore, HIF-1α silencing, in addition to treatment with A2P, dramatically and 
significantly elevated 5hmC levels compared to cells treated with A2P alone, providing evidence 
that inhibiting HIF-1α, accompanied by AA therapy, may greatly improve the demethylation of 
gene promoters and possibly the expression of tumor suppressors in melanoma. 
Collectively, the contents of this work provides in vitro evidence that the 
supplementation of melanoma cells with physiological levels of AA may be a beneficial adjuvant 
anti-cancer therapy as demonstrated by the measured decrease in malignant properties of 
metastatic melanoma cells. Decreased malignancy is likely attributed, at least in part, to the 
improved activity of multiple 2-OG dioxygenase enzymes including the HIF hydroxylases and 
TET enzymes. While additional studies are required before verifying AA supplementation as a 
bona fide adjuvant therapy for patients with melanoma, these results provide promise by 
demonstrating success at the cellular level. 
Footnotes 
1 Typically, it is convention to use the terms vitamin C and ascorbic acid (AA) 
interchangeably when discussing human physiology because in most cases the two terms 
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are referring to the same molecule. The term vitamin C is more commonly used to 
describe nutritional aspects of the molecule, while the term AA is used when describing 
the biochemistry of the molecule. However, in this work we are describing two distinct 
forms of vitamin C, reduced vitamin C (i.e. AA) and oxidized vitamin C 
(dehydroascorbic acid (DHA). In the present study, the term vitamin C is used to describe 
both forms of ascorbate (AA or DHA), total ascorbate (the summation of AA and DHA), 
or when the form of vitamin C cannot be distinguished because of assay limitations, thus 
the terms vitamin C and AA are not necessarily interchangeable. 
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CHAPTER 2 
ASCORBIC ACID AND ASCORBATE-2-PHOSPHATE DECREASE HIF ACTIVITY 
AND MALIGNANT PROPERTIES OF HUMAN MELANOMA CELLS 
 
 
The information in this chapter has been published in BMC Cancer, 15(1), 867. 
doi:10.1186/s12885-015-1878-5 
 
Miles, Fischer, Joshi, and Niles. (2015). Ascorbic acid and ascorbate-2-phosphate decrease HIF 
activity and malignant properties of human melanoma cells. BMC Cancer, 15(1), 867. 
doi:10.1186/s12885-015-1878-5 
 
Sarah L. Miles Ph.D. 
Department of Biomedical Sciences 
Joan C. Edwards School of Medicine 
Marshall University, 
One John Marshall Drive 
Huntington, WV  25755 
Email: kittlaus1@marshall.edu 
*Corresponding author 
 
Adam P. Fischer  
Department of Biomedical Sciences 
Joan C. Edwards School of Medicine 
Marshall University, 
One John Marshall Drive 
Huntington, WV  25755 
Email: fischer35@marshall.edu 
 
Sandeep J. Joshi Ph.D.       
Department of Biochemistry and Molecular Biology 
University of Maryland School of Medicine 
655 W. Baltimore Street 
Baltimore, MD 21201 
Email: SJoshi@som.umaryland.edu 
 
Richard M. Niles Ph.D. 
Department of Biochemistry and Microbiology 
Joan C. Edwards School of Medicine 
Marshall University, 
One John Marshall Drive 
Huntington, WV  25755 
Email: Niles@marshall.edu 
 
26 
 
Abstract 
Background 
Hypoxia inducible factor-1 alpha (HIF-1) is thought to play a role in melanoma 
carcinogenesis. Posttranslational regulation of HIF-1 is dependent on Prolyl hydroxylase (PHD 
1-3) and Factor Inhibiting HIF (FIH) hydroxylase enzymes, which require ascorbic acid as a co-
factor for optimal function. Depleted intra-tumoral ascorbic acid may thus play a role in the loss 
of HIF-1 regulation in melanoma. These studies assess the ability of ascorbic acid to reduce 
HIF-1 protein and transcriptional activity in metastatic melanoma and reduce its invasive 
potential.  
Methods 
HIF-1 protein was evaluated by western blot, while transcriptional activity was 
measured by HIF-1 HRE-luciferase reporter gene activity. Melanoma cells were treated with 
ascorbic acid (AA) and ascorbate 2-phosphate (A2P) to assess their ability to reduce HIF-1 
accumulation and activity. siRNA was used to deplete cellular PHD2 in order to evaluate this 
effect on AA’s ability to lower HIF-1 levels. A2P’s effect on invasive activity was measured by 
the Matrigel invasion assay. Data were analyzed by One-way ANOVA with Tukey’s multiple 
comparisons test, or Student-T test as appropriate, with p<.05 considered significant.  
Results 
Supplementation with both AA and A2P antagonized normoxic as well as cobalt 
chloride- and PHD inhibitor ethyl 3,4-dihydroxybenzoate-induced HIF-1 protein stabilization 
and transcriptional activity. Knockdown of the PHD2 isoform with siRNA did not impede the 
ability of AA to reduce normoxic HIF-1 protein. Additionally, reducing HIF-1 levels with 
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A2P resulted in a significant reduction in the ability of the melanoma cells to invade through 
Matrigel.  
Conclusion 
These studies suggest a positive role for AA in regulating HIF-1 in melanoma by 
demonstrating that supplementation with either AA, or its oxidation-resistant analog A2P, 
effectively reduces HIF-1 protein and transcriptional activity in metastatic melanoma cells. Our 
data, while supporting the function of AA as a necessary cofactor for PHD and likely FIH 
activity, also suggests a potential non-PHD/FIH role for AA in HIF-1 regulation by its 
continued ability to reduce HIF-1 in the presence of PHD inhibition. The use of the oxidation-
resistant AA analog, A2P, to reduce the ability of HIF-1 to promote malignant progression in 
melanoma cells and enhance their response to therapy warrants further investigation.  
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Background 
 Melanoma, a malignancy derived from pigment producing melanocytes found primarily 
in the epidermis of the skin, continues to be the deadliest form of skin cancer. The global 
incidence of melanoma is increasing at a faster rate than any other type of cancer. Despite 
advances in the treatment of metastatic melanoma it remains an incurable disease (Slipicevic and 
Herlyn, 2012). The only successful cure for melanoma remains early identification of atypical 
skin lesions and complete surgical excision before invasion of the deeper dermal tissue 
(Bichakjian et al., 2011; Tsao, Atkins, and Sober, 2004). After dissemination and metastasis of 
the primary tumor, limited treatment strategies have encompassed the use of conventional 
chemotherapy such as dacarbazine (Berrocal et al., 2014; Serrone, Zeuli, Sega, and Cognetti, 
2000), with only slightly more favorable responses with Interleukin-2 (IL-2), interferon–a2b 
(IFN-a2b) (Atkins et al., 2002; Tsao et al., 2004) and more recently, mutant BRAF inhibitors and 
immunostimulants (Culos and Cuellar, 2013; Gyorki, Spillane, Speakman, Shackleton, and 
Henderson, 2014; Slipicevic and Herlyn, 2012). However, even after initial positive responses, 
most melanoma tumors become chemoresistant, ultimately leading to treatment failure and 
refractory disease. 
Many factors play a significant role in the initiation and progression of melanoma 
including genetic alterations, and response to the tumor microenvironment (Bennett, 2008; 
Postovit, Seftor, Seftor, and Hendrix, 2006; Satyamoorthy and Herlyn, 2002). Within the 
microenvironment, oxygen availability is thought to play a critical role in melanoma 
carcinogenesis. Hypoxia inducible transcription factor 1 (HIF-1) is a critical mediator of the 
cellular response to hypoxia. HIF-1 is a heterodimeric complex of  and  subunits. While both 
the HIF-1 and  subunit mRNAs are constitutively expressed, the HIF-1 subunit protein is 
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tightly regulated through post-translational hydroxylation by oxygen dependent Fe II/2-
oxoglutarate (2-OG) prolyl 4-hydroxylase (PHD) enzymes (Hirsila, Koivunen, Gunzler, 
Kivirikko, and Myllyharju, 2003; Kallio, Pongratz, Gradin, Mcguire, and Poellinger, 1997). This 
hydroxylation targets HIF-ubiquitination and degradation by the proteasome. Under 
conditions of low oxygen tension, these hydroxylase enzymes are disabled, allowing the 
stabilization and accumulation of HIF-1 in the cell. 
Overexpression and stabilization of HIF-1 has been identified in numerous 
malignancies (Jiang and Feng, 2006; Kimbro and Simons, 2006; Nam et al., 2011; Semenza, 
2002), including melanoma, and has been implicated in driving its progression and metastatic 
potential (Bedogni and Powell, 2009; Giatromanolaki et al., 2003; Goda, Dozier, and Johnson, 
2003; Kuphal et al., 2010; Valencak et al., 2009; Zhong et al., 1999). Many tumor types 
including melanoma stabilize HIF-1 under non-hypoxic conditions (Krieg et al., 2000; Kuphal 
et al., 2010; Mills, Joshi, and Niles, 2009; Valencak et al., 2009). HIF acts as a positive regulator 
of proteins known to be important in melanoma cell invasion, spreading and motility (Zbytek, 
Peacock, Seagroves, and Slominski, 2013). Given the relationship between HIF-1 and 
melanoma progression, this transcription factor is an attractive target for small molecule 
inhibitors (Semenza, 2007). 
Ascorbic acid (AA) is an essential vitamin in humans due to the evolutionary loss of the 
gulonolactone oxidase (GULO) enzyme necessary to catalyze the final step in ascorbic acid 
synthesis. Its antitumor activity has been studied extensively over the past decades. Numerous in 
vitro and in vivo studies with both human and animal tumors demonstrated correlations between 
tumor AA levels, reduced HIF-1 activation, and longer disease free survival (Kuiper et al., 
2014b). Additionally, low AA levels are associated with increased HIF-1 activity and more 
30 
 
aggressive tumor phenotypes (Kuiper et al., 2010; Skrzydlewska et al., 2005). Furthermore, 
cancer patients often have depleted reserves of vitamin C (Bhagat, Ghone, Suryakar, and 
Hundekar, 2011; Esme et al., 2008; Schleich et al., 2013; Yamamoto, Yamashita, Fujisawa, 
Kokura, and Yoshikawa, 1998). AA has varying effects on cancer initiation, progression and 
growth.  
The aim of this study was to assess the effect of physiological concentrations of AA on 
the normoxic expression and activity of HIF-1 in WM9 metastatic melanoma cells and to 
determine the mechanism for its action. Because of the potential for off target pro-oxidant effects 
with the use of high concentrations of ascorbic acid (mM concentrations), our studies aimed to 
determine whether physiologically attainable serum concentrations of AA (Levine et al., 1996; 
Levine, Padayatty, and Espey, 2011), which would be achievable through the consumption of 
vitamin C rich foods (yielding up to 100 M serum AA) or oral dietary supplements (up to 250 
M serum AA), could effectively impact HIF-1 in melanoma cells (Levine et al., 2011). Under 
normoxic culture conditions, addition of AA to culture media at physiologically relevant 
concentrations resulted in a rapid reduction of HIF-1 protein, and HIF activity. Interestingly, 
the transcriptional activity of HIF-1 proved to be more sensitive to AA treatment than the PHD 
induced degradation of the HIF-1. We also found that low physiological concentrations of AA 
were also able to antagonize hypoxia-mimetic (cobalt chloride; CoCl2) induced HIF-1 
stabilization and increased HIF transcriptional activity. Ascorbate-2-phosphate (A2P), an 
oxidation resistant analog of AA, was more potent than its parent compound in reducing HIF-
1levels.  
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Materials and methods 
Cell culture and reagents 
WM1366 and WM9 melanoma cell lines were a generous gift from Dr. Meenhard Herlyn 
at the Wistar Institute (University of Pennsylvania). Cells were cultured in RPMI 1640 media 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, in a 
humidified 5% CO2 / 95% air incubator at 37C. L-Ascorbic Acid (AA), L-Ascorbic acid 2-
phosphate sesquimagnesium salt hydrate (A2P), Cobalt Chloride (CoCl2), and Ethyl 3,4-
dihydroxybenzoate (EDHB) were purchased from Sigma Chemical Company.  
Western blot analysis and antibodies 
Nuclear protein extracts were isolated using the NePER Nuclear and Cytoplasmic 
Extraction Kit (Pierce), supplemented with Complete Mini Protease Inhibitor Cocktail (Roche) 
following the manufacturers protocol. Whole cell lysates were extracted using whole cell lysis 
buffer (50 mM Tris HCl, 150 mM NaCl, 0.25% SDS, 0.25% sodium deoxycholate, 1 mM 
EDTA; pH 7.4) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Equal 
amounts of protein extracts were separated by SDS-PAGE on 4-20% MP-TGX precast 
polyacrylamide gels (BioRad), and transferred to nitrocellulose membrane using the BioRad 
MINIProtean3 system. Membranes were immunoblotted with antibodies that recognized HIF-1 
(1 l/ml; R&D Systems) or EGLN1 (PHD2; 1:1000; Cell Signaling). Anti- -actin (1:10000; 1 
hour at RT; Sigma) was used to assess equal protein loading. Immunoblots were visualized using 
an enhanced chemiluminescence detection kit (ECL Prime; GE Healthcare) and imaged on a 
PhotoDyne Imaging system (PhotoDyne Technologies). Densitometry was obtained and 
quantitated using LabQuant Software. 
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Small interfering RNA (siRNA) transfection 
WM9 cells were transfected at the time of seeding with 10 nM PHD2 siGENOME 
SMARTpool siRNA (GE Dharmacon; ThermoScientific) or 10 nM non-targeting Control siRNA 
using Lipofectamine RNAimax (Invitrogen) in standard RPMI culture media following the 
manufacturers protocol with modifications. Briefly, siRNA transfection complexes were 
combined in OptiMEM reduced serum media (Invitrogen) following the RNAimax protocol. 
Cells were removed from the dish via trypsinization, and resuspended in standard RPMI media 
containing the appropriate siRNA transfection complex. Cells were immediately seeded into 35 
mm tissue culture dishes at 1.0x105 cells per dish. Cells were incubated with transfection reagent 
overnight. Media was replaced the following day with complete RPMI +/- CoCl2, EDHB, AA or 
A2P at the concentrations and times indicated.  
Luciferase reporter assay 
2.0X105 cells were seeded in 60 mm culture dishes 24 hours prior to transfection. Cells were 
incubated overnight with transfection mixture containing 1.5 g HIF-1 pTL-Luc (5’-3’: 
GTGACTACGTGCTGCCTAGGTGACTACGTGCTGCCTAGGTGACTACGT 
GCTGCCTAGGTGACTACGTGCTGCCTAG; Affymetrix, LR0128) and 0.1 g pSV-β-
galactosidase plasmids (Clontech) and eXtreme Gene 9 transfection reagent (Roche) following 
the manufacturers protocol in OptiMEM Reduced Serum media (Invitrogen). Transfection media 
was replaced with standard RPMI the following day, and cells treated as described. Luciferase 
activity was measured using the Luciferase Assay Kit (Promega) and normalized against β-
galactosidase activity that was measured using the -galactosidase Assay Kit (Promega). 
Luciferase and -gal were measured separately on a SpectraMax M2e 96-well plate reader. 
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Matrigel invasion assay 
Prior to measuring invasion, WM9 cells were cultured in 10 cm dishes and maintained 
for 5 days in standard RPMI with or without 100 M A2P supplementation under standard 
culture conditions. Invasion was evaluated using BD BioCoat Invasion kits (354481; BD 
Corning). Cells were dissociated with Accutase (Invitrogen) and 2.5x105 cells were seeded onto 
the Matrigel coated 6-well inserts and the assay conducted using the manufacturer’s protocol 
with inclusion of 100 M A2P supplementation in all media chambers. Plates were incubated 24 
hours and cells were then fixed with 100% methanol for 5 min and stained with 0.5% crystal 
violet for 5 min before being washed several times in ddH2O to remove excess stain. Inserts 
were allowed to dry overnight, then membranes were removed from the inserts, and placed in a 
microtube with 200 L of 10% acetic acid for 15 min with vortexing to elute the dye. Sample 
absorbance was measured in triplicate at 595 nM on a SpectraMax M2e 96 well plate reader. A 
stained membrane without cells was used as the blank control to account for background 
staining.  
Reverse transcription and PCR  
Total RNA was isolated from WM9 cells using an RNeasy Mini Kit (Qiagen) following 
the manufacturers protocol. RNA quality and quantity was assessed spectrophotometrically using 
a NanoDrop 2000 UV/Vis spectrophotometer.  cDNA was synthesized from total RNA using the 
Advantage RT-for-PCR kit (Clontech Laboratories, Mount View, CA) following the 
manufacturers recommended protocol. PCR analysis of target sequences were generated using 
the Advantage cDNA kit (Clontech Laboratories) with the following PCR primers; 
EGLN1(PHD2): 5’– GGCAAAGCCCAGTTTGCTGAC-3’(forward), 5’ - 
CCCTCACACCTTTTTCACCTGT-3’ (reverse); EGLN2 (PHD1): 5’- 
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CCAGGCAAGAGAACCAGGAG-3’(forward), 5’-TCAACGTGCCTTACGTACCC-3’ 
(reverse); EGLN3 (PHD3): 5’– GGCTTCTGCTACCTGGACAACT-3’(forward), 5’- 
AGGATCCCACCATGTAGCTTG-3’ (reverse). PCR conditions: 95C 5 min; 30 cycles of 95C 
1 min, 57C 1 min, 72C 1 min; 72 5 min. PCR products were labeled with Texas Red 
(Invitrogen), separated on a 1% agarose gel and visualized by UV using a PhotoDyne Imaging 
system (PhotoDyne Technologies). Target PCR sequences were normalized to -actin.  
Statistical analysis 
Data were analyzed using GraphPad Prism 6 software (version 6.0f; GraphPad Software, 
Inc.). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple 
comparisons test, or unpaired Student-t test as appropriate. Each experiment was performed at 
least three times and represented as mean ± SEM. p<0.05 was considered as a significant 
difference.  
 
Results 
Ascorbic acid inhibits the normoxic expression of HIF-1protein in both invasive 
and metastatic human melanoma cell lines 
We previously reported (Mills et al., 2009) that when grown under normoxic culture 
conditions, normal human melanocytes and melanoma cell lines isolated from different stages of 
the disease had either no detectable HIF-1 protein (normal melanocytes) or increased amounts 
of HIF-1 protein that roughly correlated with their degree of malignancy. In our initial 
experiments, we tested the ability of physiological concentrations of ascorbic acid (AA) to 
decrease the amount of HIF-1 protein in a human melanoma cell line (WM1366), isolated from 
a vertical growth phase melanoma (Fig. 7A-B). The lowest concentration of AA (5 M) 
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dramatically decreased the normoxic expression of HIF-1 protein in this human melanoma cell 
line (Fig. 7B). An increased contrast of the western blot was used to evaluate the signal of the 
HIF-1 protein by densitometry in the AA treated samples (indicated as HIF-12  in Fig 7). 
 
Figure 7.  Effect of ascorbic acid on HIF-1 stabilization in WM1366 vertical growth phase 
melanoma cells. 
WM1366 cells were treated for 24 hours with ascorbic acid (AA; 5-50 M) under standard 
normoxic culture conditions. A) Western blot analysis of isolated nuclear extracts reveals 
considerable reduction in the amount of stabilized HIF-1 protein following treatment with AA. 
B) Densitometry analysis demonstrates the ability of AA supplementation at physiologically 
achievable concentrations to reduce the normoxic overexpression of HIF-1 by approximately 
50-60% in these cells. Protein expression was normalized to -actin. 
 
Using a metastatic human melanoma cell line (WM9), we compared the time and concentration 
dependent ability of AA or ascorbate-2-phosphate (A2P), an oxidation-resistant analog of AA, to 
decrease the level of HIF-1 protein (Fig. 8). At 15 minutes, HIF-1 protein is already 
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effectively reduced by approximately 50 % by the 50 M concentration of AA and A2P. 
However, within 30 min, the amount of HIF-1 protein was decreased by >50 % by all 
concentration in both the AA and A2P-treated WM9 cells. The decrease was maintained during 
the 2 h time period. A2P treatment most effectively reduced HIF-1 protein levels below 15 % 
by 2 hours. 
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Figure 8.  Effect of ascorbic acid and ascorbate 2-phosphate on HIF-1 stabilization in 
WM9 metastatic melanoma cells. 
WM9 metastatic melanoma cells were treated with increasing concentrations (10, 25 or 50 M) 
of ascorbic acid (AA), or the non-oxidizable analog ascorbate 2-phosphate (A2P) for 15-120 
minutes under standard normoxic culture conditions. Western blot analysis of isolated nuclear 
fractions reveals that both A) AA and B) A2P cause nearly 50% reduction of normoxic stabilized 
HIF-1 in these cells as early as 30 min following treatment. Treatment with A2P provided 
nearly complete reduction in stabilized HIF-1 by 120 min. Protein expression was normalized 
to -actin. All treatments were repeated a minimum of 2 additional times with similar results. 
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Ascorbic acid and A2P also inhibit hypoxia-mimetic-induced HIF-1protein 
stabilization 
It was important to determine whether AA and A2P could also decrease the much higher 
levels of HIF-1 found in hypoxic regions of tumors. We used CoCl2 as a mimetic of hypoxia 
since this induced a minimum 15-20 fold increase in WM9 HIF-1 protein level (Fig. 9). 
Treatment of CoCl2-treated cells with different concentrations of AA or A2P revealed that the 
latter compound was substantially more effective in reducing the amount of HIF-1 protein. 
Since 100 M A2P eliminated essentially all of the HIF-1 protein, compared to 100 M AA, 
which at this concentration had no effect on the protein, we titrated down the amount of A2P and 
found that 5 M still reduced CoCl2 induced HIF-1 by 90% (Fig. 9). 
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Figure 9. Effect of AA and A2P on cobalt chloride induced HIF-1 protein accumulation in 
metastatic melanoma. 
WM9 metastatic melanoma cells were treated for 24 hours with the hypoxia mimetic cobalt 
chloride (100 M) in the presence or absence of AA and A2P and nuclear extracts analyzed by 
western blot. A) The addition of AA (100-500 M) reveals that 100M AA is unable to reduce 
CoCl2 induced HIF-1 accumulation. Higher concentrations of AA (250 and 500 M) are 
necessary to reduce induced levels of HIF-1. B) Cells treated with A2P (5.0-100 M) show that 
A2P efficiently reduces CoCl2 induced accumulation of HIF-1 at concentrations as low as 
5M. Protein expression was normalized to -actin. All treatments were repeated a minimum of 
2 additional times with similar results. 
 
Ascorbic acid and A2P inhibit HIF-1α transcriptional activity in metastatic human 
melanoma 
While high levels of HIF-1imply induction of hypoxia-inducible genes, this needs to be 
verified by measuring HIF transcriptional activity. Therefore, we used a HIF-luciferase reporter 
plasmid transfected into WM9 metastatic human melanoma cells to examine the influence of AA 
and A2P on this activity. The hypoxia-mimetic CoCl2 induced a time dependent increase in HIF 
activity and this was antagonized by both 100 M AA and A2P, with the latter compound being 
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more effective (Fig. 10A). We also measured the concentration-dependent ability of AA and 
A2P to inhibit CoCl2-induced HIF activity (Fig. 10 B, C, D). AA at 25 M inhibited HIF activity 
by ~70 % with 50-250 M causing a further decrease in activity (Fig. 10B). In contrast, 25 M 
A2P eliminated >90 % of the HIF activity (Fig. 10C). Due to this potent effect, we treated the 
WM9 cells with 2.5-20 M A2P. There is a significant decrease (>95 %) in HIF activity at a 
concentration of 10 M A2P (Fig. 10D). 
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Figure 10. Effect of AA and A2P on HIF-1 transcriptional activity in metastatic 
melanoma. 
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase 
reporter vector. A) Transfected WM9 cells were treated with 100 M CoCl2 with or without AA 
(100 M) or A2P (100 M). Cells were collected and HIF-1 transcriptional activity was 
measured by luciferase assay at 24, 48, and 72 hours. Both AA and A2P significantly reduced 
HIF-1 transcriptional activity at 24 and 48 hours; at 72 hours, A2P significantly reduced CoCl2 
induced activity while AA began to show reduced efficacy by 72 hours. B) Dose dependent 
inhibition of CoCl2 induced HIF-1 reporter activity using 25, 50, 100 and 250 M AA. AA 
significantly reduced CoCl2 induced HIF-1 activity at all concentrations, with 25 M AA 
beginning to show reduced efficacy. C) Dose dependent inhibition of CoCl2 induced HIF-1 
reporter activity by 25, 50, 100 and 250 M A2P. All concentrations of A2P significantly 
reduced CoCl2 induced HIF-1 reporter gene activity. For this reason, lower doses of A2P were 
then tested. D) Low dose titration of A2P dependent inhibition of CoCl2 induced HIF-1 reporter 
activity using 2.5, 5.0, 10 and 25 M A2P. A2P demonstrated close to maximum inhibition of 
HIF-1 activity at concentrations as low as 10 M, with 5 and 2.5 M demonstrating little to no 
inhibition of activity. All HRE-luciferase activity was normalized to -galactosidase activity. 
Data are represented as mean ± SEM of a minimum of n=3, analyzed by One-way ANOVA 
followed by Tukey’s multiple comparisons test; * denotes significant difference from control, 
p<0.0001, # denotes significant difference from CoCl2 treatment alone, p<0.003-0.0001. 
 
PHD and AA/A2P inhibition of HIF-1α activity 
AA serves as an essential co-factor for PHD enzyme activity that results in the targeted 
degradation of HIF-1. Also, AA levels are frequently lower in human tumors than in the 
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surrounding uninvolved tissue (Kuiper et al., 2014b). Therefore, we investigated whether AA 
and A2P decreased HIF-1 protein in WM9 metastatic melanoma cells through acting on PHD. 
First, we examined whether AA and A2P could counteract the effect of the PHD inhibitor ethyl 
3,4-dihydroxybenzoate (EDHB). Fig. 11 illustrates the concentration dependent ability of EDHB 
to stimulate HIF reporter gene activity in WM9 cells. The maximum stimulation was achieved at 
750 M and this concentration was used in all further experiments. EDHB is thought to inhibit 
PDH activity through both binding to the AA site on the enzyme and by chelation of iron. Since 
AA has iron chelating activity, we tested the ability of AA to reverse the EDHB stimulation of 
HIF activity when added prior to EDHB treatment, or when the two compounds were 
simultaneously added to the cells. Cleary, AA is more effective in reversing EDHB stimulation 
of HIF activity (through inhibition of PHD activity) when pre-incubated with the cells (Fig. 11B, 
AA-EDHB) vs. adding it at the same time as EDHB (Fig. 11B, EDHB/AA).  
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Figure 11. Effect of ascorbic acid on EDHB induced HIF-1α transcriptional activity in 
melanoma cells. 
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase 
reporter vector. A) Transfected cells were treated for 24 hours with 0.5, 0.75 and 1.0 mM EDHB. 
Induction of HIF-1 transcriptional activity was measured by luciferase assay. EDHB at 0.75 mM 
was found to be the lowest dose capable of generating near-maximal induction of HIF-1 
transcriptional activity and was thus chosen for subsequent experiments. B) Cells were treated 
for 24 hours with 0.75 mM EDHB alone (EDHB), 100 M AA alone (AA), pretreated with 100 
M AA for 4 hours prior to addition of EDHB (AA-EDHB), or treated with100 M AA and 
EDHB concurrently (EDHB/AA). AA effectively reduces EDHB induced HIF-1 transcriptional 
activity; with AA pretreatment showing increased efficacy at inhibiting EDHB induced HIF-1 
activity vs. concomitant treatment. All HRE-luciferase activity was normalized to -
galactosidase activity. Data are represented as mean ± SEM of n=3, analyzed by One-way 
ANOVA followed by Tukey’s multiple comparisons test; * denotes significant difference from 
control, p<0.0001, # denotes significant difference from EDHB treatment alone, p<0.0001. 
 
Next, we compared the concentration-dependent ability of A2P vs. AA to reverse the 
EDHB-stimulated HIF activity (Fig. 12). In contrast to the superior ability of A2P vs. AA to 
inhibit cobalt chloride induced HIF-1 levels (Fig. 10), the potency of A2P and AA to inhibit the 
EDHB-induction of HIF transcriptional activity was similar.  
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Figure 12.  Effect of AA and A2P on EDHB induced HIF-1α transcriptional activity in 
melanoma cells. 
WM9 metastatic melanoma cells were transiently transfected with an HIF-1 HRE-luciferase 
reporter vector. Transfected cells were treated for 24 hours with 750 M EDHB in the presence 
of A) 2.5, 5.0, 10 or 25 M AA or B) 2.5, 5.0, 10 or 25 M A2P. HIF-1 transcriptional activity 
was measured by luciferase assay. Data are presented as the mean ± SEM of n=3, analyzed by 
One-way ANOVA followed by Tukey’s multiple comparisons test; * denotes significant 
difference from control, p<0.0001, # denotes significant difference from EDHB treatment alone, 
p<0.0001. 
 
To more directly determine whether PHD mediated the ability of AA to decrease HIF-1 
protein levels, we first determined which PHD isoforms were expressed in the WM9 cells. 
Reverse transcription-PCR analysis shows that PHD2 had the highest RNA expression followed 
by PHD1 (Fig. 13B). mRNA expression of PHD3 was not detectable. We used PHD2 siRNA to 
knockdown the expression of PHD2. The amount of PHD2 protein was reduced by greater than 
90 % in cells treated with the siPHD2 relative to cells treated with a control siRNA (Fig. 13A, 
D). Despite this dramatic decrease in PHD2 protein, AA treatment of the cells still markedly 
decreased HIF-1 protein levels. Note that the amount of HIF-1 is much higher in the siPHD2 
vs. control siRNA treated cells likely due to the absence of PHD2 (Fig. 13A, C). 
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Figure 13.  Effect of PHD2 knockdown on reduction of normoxic HIF-1 protein by AA in 
metastatic melanoma. 
WM9 metastatic melanoma cells were transfected using non-targeting control siRNA or 
siGENOME SMARTpool siRNA against PHD2. A) siRNA transfected cells were treated for 24 
hours with or without 100 M AA under standard normoxic culture conditions. HIF-1 and 
PHD2 were analyzed by western blot, and normalized to -actin. Knockdown of PHD2 caused 
an increase in stabilized HIF-1 protein; however, does not result in loss of effectiveness of AA 
to reduce accumulated HIF-1. B) qPCR analysis of PHD1, 2, and 3 isoforms in untreated WM9 
metastatic melanoma cells, normalized to -actin expression. PHD2 appears is the prevalent 
isoform, however the presences of PHD1 may contribute to the retained activity of AA following 
PHD2 selective knockdown. C, D) Densitometry analysis of HIF-1 and PHD2 expression 
following PHD2 knockdown and AA treatment. siRNA experiments were repeated a minimum 
of 2 additional times with similar results.  
 
A2P inhibits human metastatic melanoma cell invasion in vitro 
Clinical samples of human melanoma express high levels of HIF-1(Giatromanolaki et 
al., 2003; Hanna et al., 2013). Also, siRNA knockdown of HIF-1 decreases invasion of 
melanoma cell lines through Matrigel (Mills et al., 2009). Therefore, we tested whether A2P 
would also decrease the invasion of WM9 human metastatic melanoma cells. Using the Matrigel 
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in vitro invasion assay (Fig. 14) we found that treatment of the WM9 cells with A2P decreased 
invasion by 50 %. In addition, supplementation with 225 µM A2P was able to decrease 
anchorage independent growth by approximately 20 % (Fig. 15). 
 
Figure 14.  Effect of A2P treatment on invasive potential of metastatic melanoma cells. 
WM9 metastatic melanoma cells were maintained in 100 M A2P for 5 days under standard 
normoxic culture conditions. Cells were seeded into Matrigel chambers and assayed for invasion 
after 24 hours. A) Matrigel invasion assay was completed as described in Methods and Materials. 
Cells grown in the presence of A2P demonstrated a 50% reduction in invasion. B) 
Representative photographs of Matrigel invasion chambers. Data are represented as mean ± SEM 
of n=3, analyzed by Student paired T-test; * denotes significant difference from control, 
p<0.0087.  
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Figure 15.  Anchorage independent growth of WM9 cells following A2P supplementation.  
Anchorage independent growth of WM9 cells treated with A2P was assessed using CytoSelect™ 
96-Well Cell Transformation Assay (Soft Agar Colony Formation) (Cell Biolabs). Briefly, WM9 
cells were pretreated with A2P (225 µM) for 4 days before being lifted with accutase and seeded 
into 96-well plates in agar according to manufacturer’s protocol. Solidified agar was overlaid 
with 100 µL standard RPMI media containing 225 µM A2P and placed in humidified incubator 
(95 % air / 5 % CO2) for a total of 9 days. On the 6
th day media was exchanged with fresh media 
(225 µM). At time of collection, agar was solubilized and wells incubated with florescent DNA 
stain. Plate was read on a microplate reader Ex: 485/Em: 520 nm to determine total DNA 
content. Data was analyzed using Student’s unpaired T test. Error bar represents ± SEM, n = 3. * 
denotes statistical significance from control, p < 0.05. 
 
Discussion 
Once melanoma progresses to the invasive and metastatic stage, it is very difficult to 
treat. Therefore, it is important to identify the molecular changes that contribute to the malignant 
progression of this disease. Hypoxia and acquisition of a vascular network together with 
reprograming of the cancer cell’s metabolism have been noted as important events required for 
tumor progression (Kroemer and Pouyssegur, 2008; Semenza, 2002). Accumulation of HIF-1 
and HIF-2 was measured via immunohistochemistry in 46 patient samples of nodular cutaneous 
malignant melanomas (Giatromanolaki et al., 2003). Expression of HIF-1 and HIF-2 was 
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directly correlated with vascular endothelial growth factor accumulation (VEGF) and also 
associated with poor prognosis. A later study of 89 patients with primary cutaneous melanoma 
did not show a correlation between HIF-1and overall survival or disease-free survival 
(Valencak et al., 2009). However, the relative amount of HIF-1 and more importantly the 
activity of HIF as assessed by target gene expression in the samples was not assayed. HIF-1 
was found under normoxic conditions in malignant melanoma cells, but not in normal human 
melanocytes. Further, the amount of HIF-1 was increased in cells from invasive and metastatic 
human melanomas relative to that found in cells from radial growth phase melanomas. Also, 
knockdown of HIF-1 in the metastatic cells led to marked decrease in anchorage-independent 
growth and the ability to invade through Matrigel (Mills et al., 2009). Kuphal et al (Kuphal et al., 
2010) verified the constitutive expression of HIF-1 in malignant melanoma and their studies 
implicate ROS and the NF-B pathways in contributing to this accumulation of HIF-1. 
Due to their role in tumor progression, HIF-1 and HIF are targets for the development 
of new small molecular inhibitors. However, most of the inhibitors to date work in an indirect 
fashion such as Bortezomib, a proteasome inhibitor and geldanamycin, a Hsp90 inhibitor 
(Hoelder, Clarke, and Workman, 2012). In fact, medicinal chemists have deemed that HIF is 
undrugable (Hoelder et al., 2012).  
AA (vitamin C) plays a direct role in regulating both the activity of PHD and thus the 
stability of HIF-1and the activity of FIH, which inhibits the transcriptional activity of HIF. 
There are several reports that addition of AA to cancer cell lines decreases the amount of HIF-1 
protein and also inhibits HIF activity (Knowles, Raval, Harris, and Ratcliffe, 2003; Kuiper, 
Dachs, Currie, and Vissers, 2014; Vissers, Gunningham, Morrison, Dachs, and Currie, 2007). 
Thus, AA might be useful as a direct inhibitor of the HIF pathway presumably through its action 
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on the family of Fe(II)-2-oxoglutarate-dependent oxygenases, of which PHD and FIH are 
members. We investigated this possibility in human malignant melanoma cells. 
In agreement with the study of Knowles, et al (Knowles et al., 2003) we found that AA 
decreased the amount of HIF-1 protein in malignant melanoma cells grown under either 
normoxic or hypoxic-mimetic (CoCl2) conditions (Fig. 7, 8 and 9). Further, we showed that A2P, 
a less oxidizable analog of AA, was more potent than AA in reducing the amount of HIF-1 in 
the melanoma cells (Fig. 8 and 9). We could not find any other reports on the effect of A2P on 
HIF-1 levels, but several studies show that A2P inhibits tumor invasion (Liu, Nagao, 
Kageyama, and Miwa, 2000; Nagao, Nakayama, Etoh, Saiki, and Miwa, 2000), while it also 
inhibits melanogenesis in melanocytes (Kameyama et al., 1996). A2P was also more potent than 
AA in reducing HIF reporter gene activity (Fig. 10). Also note that the ability of AA to inhibit 
HIF reporter gene activity was more potent than its ability to decrease HIF-1 protein levels 
(compare Fig. 10B with Fig. 9). This finding agrees with the report of Kuiper et al (Kuiper et al., 
2014) that AA preferentially suppresses the HIF-1 transcriptional response. The authors suggest 
that this preference is likely due to AA’s ability to stabilize and reduce the iron atom in the PHD 
and FIH active sites, with FIH (asparagine hydroxylase) being more sensitive to fluctuations in 
intracellular ascorbate.  
Next, we investigated the hypothesis that the effect of AA on decreasing HIF-1 in 
human melanoma cells was mediated through stimulation of PHD and or FIH activity. First, we 
used a pharmacological inhibitor of PHD and likely FIH, ethyl-3,4-dihydroxybenzoate (EDHB). 
This inhibitor decreases prolyl hydroxylase activity (Sasaki, Majamaa, and Uitto, 1987) through 
both competition for the AA binding site (Majamaa, Gunzler, Hanauske-Abel, Myllyla, and 
Kivirikko, 1986) and inducing an iron deficiency state in cells through a low affinity for ferric 
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iron (Wang, Buss, Chen, Ponka, and Pantopoulos, 2002). In our melanoma cells, EDBH at or 
above a concentration of 750 M stimulated HIF reporter gene activity by 4-fold. Since AA 
pretreatment was more effective in blocking the EDHB stimulation of HIF-reporter gene activity 
than when EDHB and AA were added simultaneously to the cells, we suggest that there is 
competition for either the ferric iron or the AA binding site on the PHD/FIH enzymes (Fig. 11).  
After defining the condition for maximum inhibition of PHD by EDBH as measured by 
HIF-reported gene activity, we then measured the concentration-dependent ability of pre-
treatment with either AA or A2P to reverse the inhibition as determined by a decrease in HIF-
reporter gene activity (Fig. 12). In contrast to the hypoxia mimetic CoCl2 stimulation of HIF-
reporter gene activity where A2P was more potent than AA in reversing this stimulation, AA and 
A2P were similar in their potency for reversing EDHB stimulation of HIF-reporter gene activity. 
Differential response may be due to off-target (non-PHD) effects of CoCl2 causing greater 
stimulation of HIF-reporter gene activity relative to the activity induced by the PHD selective 
inhibitor, EDHB which may be more sensitive to AA supplementation.  
Since chemical inhibitors can have off-target effects, we used siRNA to knock down the 
expression of the PHD2 isoform protein. An RT-PCR survey of the expression of PHD isozymes 
in the WM9 cells revealed that these cells express predominantly PHD2 and a small amount of 
PHD1, but we could not detect expression of PHD3. The PHD2 isozyme contributes the majority 
of the HIF-hydroxylase activity in cells with normal oxygen levels (Berra et al., 2003) (Takeda 
et al., 2008). Since PHD1 is localized exclusively in the nucleus (Metzen et al., 2003), it should 
only be able to hydroxylate HIF-1 after it has been stabilized and transported into the nucleus. 
We were able to knockdown the expression of PHD2 in normoxic WM9 cells by greater than 90 
%. As shown in Fig. 13, this knockdown resulted in a 2.3 fold higher amount of HIF-1 relative 
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to cells treated with the control siRNA. Despite the knockdown of PHD2 and the increase in the 
level of HIF-1, the addition of 100 M AA still decreased the amount of HIF-1 by nearly 90 
%. There are at least two explanations for this unexpected result. One is that AA has additional 
modes of action, other than affecting prolyl hydroxylase, which result in a decrease in the HIF-
1 protein. The other possibility is that in the absence of PHD2, the isozyme PHD1 can be 
stimulated by AA and result in the targeting of HIF-1 for degradation by the proteasome. 
Regardless of the mechanism for the ability of AA and A2P to decrease HIF-1 levels 
and inhibit HIF transcriptional activity, the important question is whether blocking the HIF 
pathway decreases some of the malignant properties of the WM9 metastatic melanoma cells. We 
addressed this question by measuring the ability of WM9 cells to invade through Matrigel and 
form colonies in soft agar. A2P was able to inhibit invasion by 50 % (Fig. 14) and colony 
formation nearly 20 % (Fig. 15). A2P did not inhibit the proliferation of WM9 cells (data not 
shown). These findings, together with our previous work demonstrating that siRNA knockdown 
of HIF-1 also inhibits invasion through Matrigel (Mills et al., 2009), suggests that AA affects 
the invasive ability of these metastatic cells through a decrease in HIF-1/HIF activity.   
Although our studies used established human melanoma cell lines, there are some in vivo 
studies that link AA levels to tumor aggressiveness. Low AA levels are associated with increased 
HIF-1 levels and HIF stimulated gene products in human endometrial tumors (Kuiper et al., 
2010). In contrast, increased tumor AA is associated with longer disease-free survival and 
decreased HIF-1 and HIF stimulated gene products in human colorectal tumors.  Specifically in 
melanoma there is decreased plasma ascorbate levels in stage IV melanoma patients (Schleich et 
al., 2013) while an epidemiological study found an association between dietary vitamin C (AA) 
and the risk of cutaneous melanoma in a Northern Italian population (Malavolti et al., 2013). IL-
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2 treatment of melanoma is unfortunately associated with severe toxicity and it causes a large 
decrease in circulating levels of AA. A clinical trial has been proposed to assess the use of 
intravenous AA as an adjuvant to IL-2 treatment of melanoma (Wagner et al., 2014). Thus, AA 
has many potential roles and uses in human melanoma. The next step will be pre-clinical 
investigations of AA/A2P and HIF-1/HIF activity in animal models that most closely 
recapitulate the initiation and progression of human melanoma. 
 
Conclusion 
Our studies suggest a positive role for ascorbic acid in regulating HIF-1 in melanoma. 
The addition of ascorbic acid can effectively reduce the amount of stabilized HIF-1 found 
under normoxic conditions in both vertical growth phase WM1366 and WM9 metastatic 
melanoma cells. The addition of ascorbic acid also significantly reduces the transcriptional 
activity of HIF-1 in WM9 metastatic melanoma cells, resulting in decreased invasive potential. 
Our data support the function of AA as a critical cofactor for PHD, restoring PHD function to 
reduce protein accumulation, and likely FIH activity resulting in significant reduction of HIF-1 
transcriptional activity. However, there may also be non-PHD mediated mechanisms by which 
AA reduces the level of the HIF-1 protein. The overexpression of intra-tumor HIF-1, as well 
as ascorbic acid deficiency has been noted not only in melanoma, but in other tumor types as 
well. Further studies to evaluate the causes of ascorbic acid deficiency and its role in the loss of 
HIF-1 regulation in malignancy are needed. The use of ascorbic acid as a non-toxic adjuvant 
therapy to aid in the inhibition of HIF-1 activity in order to reduce tumor progression and 
improve patient response to clinical therapy warrants further investigation.   
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CHAPTER 3 
ASCORBIC ACID, BUT NOT DEHYDROASCORBIC ACID INCREASES 
INTRACELLULAR VITAMIN C CONTENT TO DECREASE HYPOXIA INDUCIBLE 
FACTOR -1 ALPHA ACTIVITY AND REDUCE MALIGNANT POTENTIAL IN 
HUMAN MELANOMA 
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Abstract 
Background 
Accumulation of hypoxia inducible factor-1 alpha (HIF-1α) in malignant tissue is known 
to contribute to oncogenic progression and is inversely associated with patient survival. Ascorbic 
acid (AA) depletion in malignant tissue may contribute to the aberrant normoxic activity of HIF-
1α. While the restoration of physiological AA has been shown to attenuate aberrant HIF-1α 
function in malignant melanoma, the impact of dehydroascorbic acid (DHA; oxidized AA) has 
yet to be evaluated. We investigated and compared the ability of AA and DHA to decrease the 
malignant potential of human melanoma reducing the activity of HIF-1α and restoring 
intracellular vitamin C content. 
Methods 
HIF-1α protein accumulation was evaluated by western blot and transcriptional activity 
was evaluated by reporter gene assay using a HIF-1 HRE-luciferase plasmid. Protein expression 
and subcellular localization of vitamin C transporters were evaluated by western blot and 
confocal imaging. Intracellular vitamin C content following AA, ascorbate 2-phosphate (A2P), 
or DHA supplementation was determined using a vitamin C assay. Malignant potential was 
accessed using a 3D spheroid invasion assay. Data was analyzed by One or Two-way ANOVA 
with Tukey’s multiple comparisons test as appropriate with p < 0.05 considered significant. 
Results 
Melanoma cells expressed sodium dependent vitamin C (SVCT2) and glucose (GLUT1) 
transporters necessary for the uptake of AA and DHA; however, advanced melanomas only 
responded favorably to AA, not DHA. Under physiological glucose (1 g/L) conditions, DHA 
supplementation resulted in reduced intracellular vitamin C content, contributing to elevated 
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HIF-1α activity and increased invasion when compared to AA/A2P supplemented cells. The 
ability of AA to regulate HIF-1α was dependent on SVCT2 function, and SVCT2 was not 
significantly inhibited at pH a representative of the tumor microenvironment. 
Conclusions 
The use of ascorbic acid as an adjuvant cancer therapy remains under investigated. While 
AA and A2P was capable of modulating aberrant HIF-1α protein accumulation/activity, DHA 
supplementation resulted in the eventual loss of vitamin C activity, contributing to its decreased 
ability to inhibit HIF-1α and invasion in advanced melanoma. Restoring AA dependent 
regulation of HIF-1 in malignant cells may prove beneficial in reducing chemotherapy 
resistance and improving treatment outcomes. 
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Background 
 The incidence of melanoma, a malignancy derived from pigment producing melanocytes, 
has continually risen over the past 30 years and accounts for 75 % of skin cancer deaths. In 2016 
an estimated 76,000 new cases of skin melanoma will be diagnosed in the United States, 
contributing to over 10,000 fatalities by year’s end (Siegel et al., 2016). Most cutaneous 
melanomas can be readily cured by surgical excision (Bichakjian et al., 2011; Tsao et al., 2004), 
however once disseminated, metastatic melanoma is highly aggressive and difficult to treat. Five 
year survival of melanoma patients declines from 98 to 17 % following metastasis to a distant 
site (Siegel et al., 2016). Even though clinical responses have improved through the use of 
immunotherapy, poor patient prognosis, attributed to chemotherapy resistance, highlights the 
need for alternative or adjuvant treatment options to improve survival in melanoma patients. 
 Melanoma oncogenesis is predominantly driven by the acquisition of BRAF mutations; 
50 % of all melanomas contain either a V600E or V600D BRAF mutant (Ascierto et al., 2012). 
This mutation results in the constitutive activation of signaling pathways leading to unchecked 
cell proliferation, invasion, and metastasis. Constitutive BRAF activation is also known to 
contribute to elevated gene expression of hypoxia inducible factor-1 alpha (HIF-1α) (Kumar et 
al., 2007), the oxygen responsive subunit of the HIF-1 transcription factor. HIF-1 activity in 
malignant tissue contributes to increased expression of proteins that drive melanoma cell motility 
and invasion (Zbytek et al., 2013). Elevated expression of HIF-1α protein is widespread in 
malignant tissue, including melanoma (Konstantina, Lazaris, Ioannidis, Liossi, and Aroni, 2011), 
and has been linked to poor patient outcomes in a variety of cancers (reviewed in (Semenza, 
2010)). Ascorbic acid (AA; reduced vitamin C) is an essential cofactor for Fe II/2-oxoglutarate 
dioxygenase enzymes, including the prolyl hydroxylase (PHD1-3) and factor-inhibiting HIF 
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(FIH) hydroxylase enzymes that regulate HIF-1α protein stability and transcriptional activity 
respectively (Flashman et al., 2010; Kuiper and Vissers, 2014c). Plasma AA concentration in 
healthy individuals is typically between 40 – 80 µM (Du et al., 2012b). Interestingly, cancer 
patients, including those with melanoma (Schleich et al., 2013), have been observed to have 
below normal levels of plasma AA (Fain et al., 1998; Huijskens, Wodzig, Walczak, Germeraad, 
and Bos, 2016; Mayland, Bennett, and Allan, 2005; Mikirova, Casciari, Riordan, and 
Hunninghake, 2013). Likewise, tumor tissue has been found to contain decreased intracellular 
AA compared to paired non-transformed tissue from the same patient (Kuiper et al., 2010). The 
degree of AA deficiency in malignant tissue also correlates with increased tissue accumulation of 
HIF-1α protein and with tumor stage (Kuiper et al., 2014b; Kuiper et al., 2010), suggesting that 
inadequate intracellular AA may contribute to the development or progression of a malignant 
phenotype. 
The majority of current studies investigating AA as an anti-cancer therapy utilize I.V. 
administered mega or high dose (> 1 mM) AA supplementation to induce cytotoxic cell death; 
however, the potential benefit and use of AA supplementation at physiological concentrations to 
restore or support its cofactor functions in malignant cells has remained largely unexplored and 
uncharacterized. Recently, we reported that supplementation of human metastatic melanoma 
cells with physiological concentrations (10-100 M) of ascorbic acid inhibits both normoxic and 
hypoxia-mimetic induced protein accumulation and transcriptional activity of HIF-1α, and 
reduces the malignant potential of these cells (Miles, Fischer, Joshi, and Niles, 2015; Mills et al., 
2009), emphasizing the functional importance of physiological levels of AA in malignant cells. 
In vivo studies using GULO -/- mice (a model of human AA dependency) inoculated with 
murine melanoma cells demonstrate that AA supplementation can decrease tumor accumulation 
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of HIF-1α (Campbell et al., 2014) and decrease tumor volume (Campbell et al., 2014; Cha et al., 
2011; Cha et al., 2013). Furthermore, tumor ascorbate levels inversely correlated to the 
expression of HIF-1 target genes (Campbell et al., 2014), providing further support for initiating 
the use of AA as an adjuvant cancer therapy. 
 Dietary vitamin C is comprised of both reduced AA and the fully oxidized form, 
dehydroascorbic acid (DHA). The ability of AA and DHA to provide equivalent intracellular 
vitamin C activity has been controversial for decades with conflicting reports on the ability of 
DHA intervention to prevent or treat scurvy in animal and human subjects (Frikke-Schmidt, 
Tveden-Nyborg, and Lykkesfeldt, 2016; Ogiri et al., 2002; Otsuka, Kurata, and Arakawa, 1986; 
Todhunter, Mc, and Ehmke, 1950). Recently, McCarty (Mccarty, 2013) speculated that DHA 
would be a more effective cancer therapy than AA. The rationale for this idea was that advanced 
malignancies, particularly those with elevated HIF activity, often overexpress glucose 
transporters (GLUTs), a common observation in Warburg metabolism (Courtnay et al., 2015). 
Interestingly, DHA uptake is facilitated by GLUTs, therefore elevated GLUT1 expression, which 
is a known HIF-1 target gene, would support increased DHA entry into malignant cells (Mccarty, 
2013). DHA itself does not have any biological activity or act as an enzyme cofactor; however, 
once transported into the cell, it is reduced to AA in the cytosol, providing the functional form of 
vitamin C (Fig. 16) (Du et al., 2012b). To our knowledge, the capacity of using DHA rather than 
AA as an effective clinical source for increasing intracellular AA levels has not been evaluated 
in malignant cells.  
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Figure 16.  Major degradation products of ascorbic acid. 
Ascorbic acid (AA) becomes fully oxidized to dehydroascorbic acid (DHA) following the 
donation of electrons to either enzyme cofactors or free radicals. Intracellular DHA can 
subsequently be reduced and recycled to AA by multiple DHA reductases or glutathione, 
facilitating comparatively higher levels of AA in tissues and plasma. Alternatively, impaired 
reductase or glutathione activity promotes the spontaneous and irreversible degradation of DHA 
to 2,3-diketogulonic acid (2,3-DKG) resulting in the loss of vitamin C. Cleavage between the 
second and third carbon atoms of 2,3-DKG causes the formation of L-erythrulose and oxalic 
acid, the latter being a primary metabolite of AA. 
 
 There are several physiological factors that may impair the delivery of adequate vitamin 
C to melanoma cells via AA or DHA supplementation. Some of these include the expression and 
subcellular localization of sodium dependent vitamin C transporters (SVCT1 and 2) and glucose 
transporters (GLUTs), which transport AA and DHA, respectively. DHA competes with glucose 
for entry into the cell through the GLUT transporters and is known to be unstable at 
physiological pH (Linster and Van Schaftingen, 2007). Therefore, the effect of glucose 
competition on DHA uptake poses a relevant concern for the use of DHA in the clinical setting 
as a means to promote intracellular vitamin C accumulation and warrants evaluation. The 
objective of this study was to compare the suitability of AA vs. DHA as a potential adjuvant 
cancer therapy. This objective was accomplished by examining the ability of AA and DHA to 
reduce the malignant potential of melanoma cells by increasing intracellular vitamin C content 
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and subsequently restoring regulation of aberrant normoxic HIF-1 protein accumulation and 
activity in human melanoma cells.  
Materials and methods 
Cell culture and reagents 
WM3211, SbCl2, WM3248, WM1366, WM239A, and WM9 melanoma cell lines were a 
generous gift from Meenhard Herlyn’s lab at the Wistar Institute (University of Pennsylvania). 
Human Epidermal Melanocytes, neonatal, lightly pigmented (HEMnLP) were purchased from 
Life Technologies. All cells were cultured in a humidified incubator with 5 % CO2 / 95 % air at 
37°C. SbCl2 cells were cultured in MCDB 153 media (Sigma) supplemented with 2 % fetal 
bovine serum (FBS), 5 µg/mL insulin (Sigma), 1.68 mM CaCl2, and 1 % penicillin/streptomycin. 
WM3211 cells were cultured similarly except for 5 % FBS without CaCl2. WM3248, WM1366, 
WM239A, and WM9 cells were cultured in standard RPMI 1640 media (Gibco; 1 g/L glucose as 
indicated in text) supplemented with 10 % FBS and 1 % penicillin/streptomycin. HEMnLP cells 
were cultured in Medium 254 (ThermoFisher) supplemented with Human Melanocyte Growth 
Supplement (HMGS; ThermoFisher) and 1 % gentamicin/amphotericin B. L-Ascorbic Acid 
(AA), Dehydroascorbic acid (DHA), L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate 
(A2P), Ethyl 3, 4-dihydroxbenozoate (EDHB), and Cobalt Chloride (CoCl2) were purchased 
from Sigma. Glucose Transporter Inhibitor III; STF-31 was purchased from EMD Millipore. 
Western blots 
Membrane protein enriched fractions were prepared by trypsinizing and resuspending 
cells in a non-detergent buffer (250 mM sucrose, 10 mM Tris, 1 mM EDTA; pH 7.5) and passing 
through a 26G needle. The homogenate was centrifuged for 1 h at 16000 x g (4 degrees C). The 
resulting pellet was lysed (150 mM NaCl, 20 mM Tris, 1 mM EDTA, 1 mM EGTA, 0.75 % 
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Trition X-100, 0.25 % SDS; pH 7.5) for 1 h on ice and centrifuged for 10 min at 16000 x g (4 
degrees C) to collect the supernatant. Nuclear protein extracts were isolated using the NePER 
Nuclear and Cytoplasmic Extraction Kit (Pierce) following the manufacturers protocol. All 
buffers were supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Protein 
lysates were separated by SDS-PAGE on 4-20 % MP-TGX precast polyacrylamide gels 
(BioRad) and transferred to nitrocellulose using BioRad MINIProtean3 system. Membranes were 
immunoblotted with antibodies against SVCT2 (1:500; Santa Cruz), GLUT1 (1:5000; abcam), 
HIF-1α (1µL/mL; R&D Systems). Equal lane loading was accessed by visualization of total 
protein using MemCode™ Reversible Protein Stain Kit (Thermo Scientific) or probing for βactin 
(1:10000; 1.5 h at RT; Sigma). Immunoblots were visualized using an enhanced 
chemiluminescence detection kit (ECL Prime; GE Healthcare) and imaged on a PhotoDyne 
Imaging system (PhotoDyne Technologies). All western blot images are representative of three 
different experiments or biological repeats with similar results as indicated in figure legends. 
Luciferase reporter assay 
Reporter assays were conducted as previously described (Miles et al., 2015). Briefly, 2.0 
X 105 cells were seeded in 60 mm culture dishes 24 h prior to transfection. Cells were incubated 
overnight with transfection mixture containing 1.5 μg HIF-1 pTLLuc(5’-3’: 
GTGACTACGTGCTGCCTAGGTGACTACGTGCTGCCTAGGTGACTACGT 
GCTGCCTAGGTGACTACGTGCTGCCTAG; Affymetrix, LR0128) and 0.1 μg pSV-β-
galactosidase plasmids (Clontech) and eXtreme Gene 9 transfection reagent (Roche) following 
the manufacturers protocol in OptiMEM Reduced Serum media (ThermoFisher). Transfection 
media were replaced with standard RPMI the following day, and cells were treated as described. 
Luciferase activity was measured using the Luciferase Assay Kit (Promega) and normalized 
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against β-galactosidase activity that was measured using the β-galactosidase Assay Kit 
(Promega). Luciferase and β-gal were measured separately on a SpectraMax L and SpectraMax 
M2e plate reader (Molecular Devices) respectively. 
Reverse transcription (RT) and PCR 
Total RNA was isolated from WM9 cells using an RNeasy Mini Kit (Qiagen) following 
the manufacturers protocol. mRNA quality and quantity was assessed spectrophotometrically 
using a NanoDrop 200 UV/Vis spectrophotometer. cDNA was synthesized from total mRNA 
using the Advantage RT-for-PCR kit (Clonetech Laboratories) following the manufacturers 
protocol. PCR analysis of target sequences were generated using the Advantage cDNA kit 
(Clonetech Laboratories) with the following PCR primers; GLUT1: 5’ - 
TCATCAACCGCAACGAGGAG – 3’(Forward), 5’ – CAAAGATGGCCACGATGCTC – 3’ 
(Reverse); BNIP3: 5’ – TGGACGGAGTAGCTCCAAGA – 3’ (Forward), 5’ – 
TCATGACGCTCGTGTTCCTC – 3’ (Reverse); βactin: 5’ – GCTGCTCGTCGACAACGGCTC 
– 3’ (Forward), 5’ – CAAACATGATCTGGGTCATCTTCTC – 3’ (Reverse). PCR condition: 95 
°C 1 min; 25 cycles of 95 °C 30 sec, 57 °C 1 min, 72 °C 2 min; 72 °C 5 min. PCR products were 
separated on 1 % agarose gel containing GelRed™ nucleic acid stain (Biotium) and visualized 
by UV using a PhotoDyne Imaging system (PhotoDyne Technologies). cDNA and PCR products 
were generated using MJ Mini Personal Thermal Cycler (Biorad). 
Confocal imaging 
Melanoma cells were grown under standard conditions on chambered tissue culture slides 
(BD Falcon™). To visualize the plasma membrane, cells were incubated with wheat germ 
agglutinin (WGA) conjugated with Alexa Fluor® 594 (Invitrogen) for 10 min (2 µg/mL) before 
being fixed using 3.7 % formaldehyde in PBS (10 min). Cells were washed 3 X with PBS-T then 
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permeabilized using PBS-T containing 0.1 % Triton X-100 (5 min) and blocked with 5 % BSA 
for 1 h at RT. Fixed cells were incubated overnight at 4 degrees C with SVCT2 (1:50; Santa 
Cruz) or GLUT1 (1:250; Abcam) antibodies. Following PBS-T wash, cells were incubated with 
donkey anti-goat IgG-FITC (1:100; Santa Cruz) or donkey anti-rabbit IgG H&L (Alexa Fluor® 
488) (1:500; Abcam) respectively for 2 h. Slides were mounted using VECTASHIELD Hard Set 
mounting medium (Vector Laboratories). Images were acquired at The Marshall University 
Molecular and Biological Imaging Center using a Leica SP5 TCSII (Leica Microsystems). A 63x 
glycerol lens (NA 1.3) was used to collect a series of images in z-axis with focus steps of 0.5 
µm. Total thickness of z-series (approximation of cell mono-layer thickness) ranged from 2.5 – 4 
µm. Z-series are shown here as single image maximum intensity projections. Image format is 
2048 x 2048 pixels representing a square area of 156 µm x 156 µm (each pixel 76 nm x 76 nm). 
Emissions from Alexa Fluor® 594 (plasma membrane) were collected by photo-multiplier tube 
(PMT) through a slit passing light 575 – 650 nm with excitation from 561 nm solid state laser. 
Emissions from FITC and Alexa Fluor® (SVCT2 and GLUT1) were collected by PMT through a 
slit passing light 500 – 550 nm with excitation from 496 nm line of argon gas laser. Images were 
processed using ImageJ v 1.50g. 
Intracellular vitamin C assay 
Intracellular vitamin C (as AA and/or DHA) content was determined using a protocol 
adapted from Vislisel et al. (Vislisel, Schafer, and Buettner, 2007). In brief, cells were seeded 
similarly into 10 cm plates to ensure equivalent confluence at time of collection. At the time of 
vitamin C supplementation, cells were incubated in transport buffer (15 mM Hepes, 135 mM 
NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, pH 7.4) unless otherwise indicated in text, or 
in RPMI. After incubation, cells were trypsinized and cell pellets lysed on ice in methanol water 
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(60 MeOH:40 H2O ratio) for 10 min before centrifugation at 12,000 x g for 10 min at 4 °C. 
Supernatant along with freshly prepared ascorbic acid standards (100 µL) were aliquoted into a 
96-well plate with the addition of 100 µL 4-hydroxy-2,2,6,6-tetramethyl-piperidinooxy 
(TEMPOL; Acro Organics; 2.32 mM) and incubated for 10 min at RT. Immediately, 42 µL of o-
phenylenediamine dihydrochloride (OPDA; Thermo Scientific; 5.5 mM) were added to samples 
and incubated 10 min at RT in the dark before endpoint fluorescence was read on a SpectraMax 
M2e plate reader (Molecular Devices) at Ex 345/Em 425 nM. 
Tumor spheroid formation and 3D invasion assays 
Multicellular tumor spheroid formation and 3D invasion assays were adapted from Vinci 
et al. (Vinci, Box, and Eccles, 2015). Briefly, WM9 cells were seeded as a monolayer and 
pretreated with or without A2P or DHA (100 µM) for four days. Thereafter, cells were detached 
and 1 X 104 cells were seeded into round bottom 96-well plates coated with agarose and 
incubated for 48 h under standard culture conditions to encourage spheroid formation. Spheroids 
were then suspended in basement membrane matrigel matrix (final conc. 3.5 mg/mL; BD 
Biosciences) and overlaid with RPMI (1 g/L glucose) with or without A2P or DHA (100 µM) for 
up to 96 h with images collected every 24 h using a Zeiss primovert microscope (Zeiss) to 
measure the diameter of the spheroid including the migrating cells. Cells and spheroids were 
cultured in RPMI media (1 g/L glucose) for the duration of the experiment (pre and post 
matrigel). Images were analyzed using ImageJ v 1.50g. 
Statistical analysis 
Data was analyzed using GraphPad Prism 6 software (version 6.0f; Graphpad Software, 
Inc.). Statistical significance was determined by One-way or Two-way ANOVA followed by 
Tukey multiple comparison tests as appropriate. Three individual trials were performed for each 
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experiment and data represented as mean ± SEM. p < 0.05 was considered statistically 
significant. Specific p values are indicated in figure legends.  
 
Results 
A2P and AA inhibit hypoxia-mimetic induced HIF-1α protein stability and 
transcriptional activity more effectively than DHA in human melanoma cells 
In our initial experiment, we wanted to compare the ability of ascorbate 2-phosphate 
(A2P) vs. DHA to inhibit the hypoxia-mimetic ethyl 3, 4-dihydroxbenozoate (EDHB) induced 
stability of HIF-1α protein in WM9 and WM239A metastatic melanoma cells following a 24 h 
treatment. EDHB is a specific inhibitor of PHDs, binding the ascorbate and 2-oxoglutarate sites 
of the enzyme (Majamaa et al., 1986). AA is known to have a short half-life in culture media due 
to rapid oxidation (Frikke-Schmidt and Lykkesfeldt, 2010; Michels and Frei, 2013); therefore 
A2P, which is an oxidation resistant analog of AA, was utilized as our source for vitamin C in 
longer time point studies. Similar to our previous report (Miles et al., 2015), we demonstrated 
that all concentrations of A2P (100-500 M) cause nearly complete abolishment of EDHB 
induced HIF-1α protein expression at 24 h, while only by the highest concentration of DHA (500 
µM) was capable of reducing EDHB induced HIF-1 (Fig. 17). 
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Figure 17.  Comparison of A2P and DHA to reduce EDHB induced HIF-1α protein 
accumulation in metastatic melanoma. 
WM9 and WM239A metastatic melanoma cells were incubated in RPMI (1 g/L glucose) 
containing EDHB with or without increasing concentrations (100 – 500 µM) of A2P or DHA as 
indicated for 24 h. Our data demonstrates A2P supplementation is more effective than DHA in 
decreasing HIF-1α stability and accumulation. Blots are representative of three experiments with 
similar results. 
 
Since AA also functions as a cofactor for FIH to regulate the transcriptional activity of 
HIF-1, we wanted to compare the ability of various vitamin C compounds to decrease the 
transcriptional activity of HIF-1α in melanoma cells. Therefore, we transiently transfected 
normal human melanocytes (HEMnLP) and a panel of five established human melanoma cell 
lines with a HIF-1 HRE-luciferase reporter plasmid prior to being stimulated with the hypoxia 
mimetic cobalt chloride (CoCl2) with or without 100 µM A2P, AA, or DHA for 24 h. As 
expected, HIF-1α activity was not inducible in HEMnLP cells (Fig, 18A). Interestingly, all 
compounds demonstrated a similar ability to decrease transcriptional activity in WM3211 and 
SbCl2 cells (Fig. 18B-C), which demonstrated only modest induction of HIF-1 activity. 
Conversely, DHA was unable to decrease HIF-1 activity in WM3248, WM1366, and WM9 
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cells while AA, in particular A2P, significantly suppressed CoCl2 induced HIF-1α transcriptional 
activity (Fig. 18D-F).  
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Figure 18.  Survey of HIF-1α transcriptional activity following supplementation of vitamin 
C compounds in melanoma cells. 
Normal melanocytes (HEMnLP) and a panel of melanoma cells were transiently transfected with 
an HIF-1 HRE-luciferase reporter vector. Following overnight transfection, cells were treated 
with the hypoxia-mimetic CoCl2 (100 µM) with or without 100 µM A2P, AA, or DHA for 24 h. 
Our results demonstrate A) HEMnLP cells do not have inducible HIF-1 activity, while B) 
WM3211 and C) SbCl2 cells are responsive to all vitamin C compounds. D) WM3248, E) 
WM1366, and F) WM9 cells were all responsive to A2P and AA, but not DHA. Data was 
analyzed using One-way ANOVA with a Tukey multiple comparison test. Error bars represent 
SEM, n = 3. * denotes statistical significance from CoCl2 induced cells p < 0.05; ** p < 0.01; 
*** p < 0.001; **** p < 0.0001. # denotes statistical significance from DHA treated cells p < 
0.05; ## p < 0.01; #### p < 0.0001. Data was normalized as percent of control (control = 100 %; 
not shown). 
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Consistent with the about results (Fig. 18F), we also found that incubation of WM9 cells 
with 100 µM A2P for 24 h was more effective than DHA in inhibiting HIF-1 induced mRNA 
expression of GLUT1 and BNIP3, classic HIF-1 target genes (Fig. 19A-C). 
 
Figure 19.  Regulation of HIF-1α target gene expression by A2P or DHA. 
To evaluate the impact of vitamin C compounds on HIF-1 target gene mRNA expression, HIF-1 
transcriptional activity was stimulated in WM9 cells using CoCl2 (100 µM) and co-treated with 
100 µM A2P or DHA for 24 h before cDNA was generated from isolated total RNA. A) 
Traditional PCR using primers for classic HIF-1 target genes (GLUT1 and BNIP3) reveals A2P 
supplementation more effectively decreases HIF-1 target gene mRNA expression compared to 
DHA. B, C) Densitometry of GLUT1 and BNIP3 mRNA expression. Data is representative of 
multiple individual experiments with similar results. 
 
 
Human melanoma cells express SVCT2 and GLUT1 transporters necessary for AA 
and DHA transport 
 The inability of DHA supplementation to reduce HIF-1α transcriptional activity among 
the melanoma cell lines may be due to differences in the expression and subcellular localization 
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of vitamin C transporters in the different cell lines. Sodium dependent vitamin C transporters 
(SVCT1 and 2) facilitate cellular transport of reduced vitamin C (ascorbic acid; AA). The 
primary function of SVCT1 is dietary absorption and reabsorption, therefore expression of this 
isoform is typically confined to intestinal enterocytes and renal tubule cells, as well as liver and 
lung tissue, providing adequate circulating AA in the plasma (Corti et al., 2010; Lindblad et al., 
2013; May, 2011). SVCT2 expression is wide spread throughout most tissues and organ systems, 
facilitating uptake and intracellular accumulation of AA from the plasma (Corti et al., 2010; 
Lindblad et al., 2013). The oxidized form of AA (DHA) is transported by glucose transporters 
(GLUTs), primarily GLUT1 and 3 (Du et al., 2012b; Liang et al., 2001; Lindblad et al., 2013). 
Following uptake, DHA can be reduced back to AA enzymatically by DHA reductases or, to a 
lesser extent, non-enzymatically by glutathione (Fig. 16) (Linster and Van Schaftingen, 2007). 
To evaluate the potential contribution of differential transporter expression and localization on 
aberrant HIF-1 activity and subsequent ability of AA and DHA to modulate HIF-1 stability 
and activity, we first evaluated the protein expression of SVCT2 and GLUT1 transporters in 
HEMnLP and melanoma cells by western blot. All cell lines were found to express both SVCT2 
and GLUT1 proteins (Fig. 20A). Subsequent PCR analyses confirmed that SVCT2 and GLUT1 
are the primary isoforms expressed in these cell lines (data not shown).  
 To effectively transport extracellular AA or DHA into the cell, SVCT2 and GLUT1 
transporters must be localized to the plasma membrane. Therefore, we examined the subcellular 
localization of SVCT2 and GLUT1 in WM3211 and WM9 melanoma cells. These cells were 
chosen for this experiment because they possess similar protein expression of GLUT1 (Fig. 
20A), yet were either responsive (WM3211) or non-responsive (WM9) to DHA. Our results 
demonstrate that the majority of SVCT2 protein appears to be internalized in both cell lines (Fig. 
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20B) while GLUT1 appears to be localized primarily to the plasma membrane (Fig. 20C). Thus, 
the ability of melanoma to utilize DHA as a source of AA to reduce HIF-1 activity does not 
appear to be a consequence of altered or differential GLUT1 protein expression or localization. 
 
Figure 20.  Protein expression and subcellular localization of SVCT2 and GLUT1 in 
human melanoma. 
A) Western blot analysis of cell membrane enriched protein extracts reveal varying expression of 
SVCT2 and GLUT1 isolated from melanocytes (HEMnLP) and a variety of melanoma cell lines. 
B) Confocal analysis of WM3211 and WM9 cells depicts the majority of SVCT2 protein is 
internalized and not present within the plasma membrane. Conversely, C) the expression of 
GLUT1 is primarily limited to the plasma membrane. Confocal images are representative of 
multiple experiments. 
 
AA and DHA supplementation leads to the accumulation of vitamin C in WM9 
metastatic melanoma cells  
To further elucidate why DHA appeared to be ineffective at enhancing the intracellular 
cofactor function of AA, WM9 cells were used as the study model in the remainder of this 
72 
 
investigation because they represent an advanced metastatic phenotype, providing a more 
clinically relevant model for evaluating the use of AA or DHA as an adjuvant therapy in 
melanoma. To evaluate intracellular vitamin C accumulation, we compared the ability of AA and 
DHA to increase intracellular vitamin C content in WM9 metastatic melanoma cells. Cells were 
incubated for 30 min with AA or DHA (100 µM). Cells were treated with AA rather than A2P 
because A2P must first be dephosphorylated by cell surface phosphatases or esterases before it 
can be transported by SVCTs (Chepda, Cadau, Girin, Frey, and Chamson, 2001; Fujiwara et al., 
1997). This dependence on phosphatases is known to delay the initial transport of AA (Vislisel et 
al., 2007) an observation our laboratory also confirmed (data not shown). Mechanistically, the 
vitamin C assay operates by oxidizing the AA present in the sample to DHA before the addition 
of o-phenylenediamine (OPDA). DHA and OPDA then react to form a fluorescent condensation 
product (Vislisel et al., 2007), thus this assay quantifies total intracellular vitamin C (AA and 
DHA) content and does not distinguish between AA and DHA. At short time points, intracellular 
vitamin C content was significantly higher following DHA incubation compared to AA (Fig. 
21A), supporting previous findings (Spielholz, Golde, Houghton, Nualart, and Vera, 1997). 
However, the effect of glucose competition on DHA transport was not accounted for under these 
transport conditions. Therefore, studies were repeated in the presence of physiological glucose (1 
g/L; 5.5 mM) and demonstrated that glucose significantly attenuated the accumulation of 
intracellular vitamin C in the presence of DHA while having no impact on the ability of AA to 
raise intracellular vitamin C levels. The addition of glucose to the incubation buffer resulted in 
similar initial accumulation of intracellular vitamin C using either the SVCT2/AA or 
GLUT1/DHA transport system (Fig. 21A). To validate that vitamin C accumulation following 
DHA incubation was due to DHA uptake by GLUT1 transport, vitamin C accumulation studies 
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were also done in the presence of the highly selective GLUT 1 inhibitor STF-31 (10 µM). 
Inhibition of GLUT1 significantly reduced DHA uptake and confirmed that DHA transport was 
mediated by GLUT 1 (Fig. 21A). 
 To confirm that AA or DHA supplementation results in functionally equivalent 
intracellular AA, the protein accumulation of HIF-1α in WM9 cells was evaluated by western 
blot. During a short incubation (30 min), all concentrations (10-50 m) of AA nearly eliminated 
hypoxia-mimetic (EDHB) induced HIF-1α accumulation, while only the highest concentration of 
DHA (50 M) was able to reduce HIF-1 protein levels (Fig. 21B). 
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Figure 21. Initial transport and activity of AA or DHA in WM9 melanoma cells. 
To evaluate the contribution of GLUT1 to vitamin C accumulation in metastatic melanoma, A) 
WM9 cells were incubated with AA or DHA (100 µM) for 30 min. in a standard transport buffer 
with or without glucose (1 g/L) or the GLUT1 inhibitor STF-31 (10 µM), before being collected 
and intracellular vitamin C measured. B) To compare the initial ability of AA or DHA to 
decrease HIF-1α protein stability and accumulation WM9 cells were incubated with EDHB (750 
µM) for 2 h before the media was exchanged with fresh RPMI (1 g/L glucose) containing low 
concentrations (10 – 50 µM) of AA or DHA for 30 min before nuclear protein extracts were 
analyzed by western blot. Our results demonstrate that in the absence of glucose DHA appears to 
be preferentially transported across the plasma membrane over AA, resulting in a higher initial 
intracellular vitamin C content. However, the addition of glucose significantly attenuates DHA 
transport as seen by loss of intracellular accumulation of vitamin C. The use of STF-31 similarly 
inhibits DHA transport confirming GLUT1 is the primary mechanism for DHA uptake. Western 
blot analysis indicates that at all concentrations AA was more effective at regulating HIF-1α 
protein stability than DHA. Data was analyzed using Two-way ANOVA with a Tukey multiple 
comparison test. Error bars represent SEM, n = 3. # denotes statistical difference from buffer 
only AA, p < 0.0001. * denotes statistical difference from buffer only DHA, p < 0.0001. ns = not 
significant. AA content was not detectable in control cells so significance is not indicated.  
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Prolonged incubation with DHA results in the loss of intracellular vitamin C 
 Our results demonstrated that the presence of glucose attenuated the initial DHA 
transport into cells; therefore, we wanted to determine if this would impact the ability of cells to 
accumulate and maintain intracellular vitamin C over time, thus representing a more 
physiologically and clinically relevant scenario for assessing the therapeutic potential of AA and 
DHA. To evaluate the accumulation of vitamin C at longer time points, WM9 cells were 
supplemented with 100 µM A2P, AA, or DHA for 24, 48, and 72 h under standard culture 
conditions (Table 2). To maintain the health of the cells during the extended time point 
incubations, transport buffer was substituted with standard RPMI media containing (1 g/L) 
glucose. Following incubation, cells were collected and the total vitamin C content measured 
using the vitamin C assay. Our results show supplementation with A2P resulted in significantly 
higher intracellular vitamin C compared to either AA or DHA at both 24 and 48 h. Intriguingly, 
in contrast to shorter time points, incubation with DHA at all longer time points (24 – 72 h) 
resulted in minimal vitamin C content in our cells (Table 2), suggesting a limited therapeutic 
capacity for DHA compared to AA and A2P. 
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                 Vitamin C (100 µM)     mmoles per 10
6
 cells 
24 h 
A2P                              4.700 ± 0.333  
AA                                2.907 ± 0.184 ** 
DHA                             0.163 ± 0.029 *** # 
48 h 
A2P                              2.500 ± 0.411  
AA                                0.847 ± 0.428 * 
DHA                             0.020 ± 0.020 ** 
72 h 
A2P                              0.390 ± 0.189 
AA                                ND 
DHA                             0.033 ± 0.015 
 
Table 2.  Intracellular accumulation of vitamin C following incubation with various 
vitamin C compounds. 
WM9 cells were incubated with 100 µM A2P, AA, or DHA for the indicated time period in 
RPMI media containing 1 g/L glucose. Incubation with A2P resulted in the greatest vitamin C 
content compared to AA and DHA. Interestingly, minimal vitamin C accumulation resulted from 
DHA incubation. Data was analyzed using One-way ANOVA with a Tukey multiple comparison 
test within each time period. Data shown as ± SEM, n = 3. * denotes significance from A2P at 
the indicated time period, p < 0.05; ** p < 0.01; *** p < 0.0001. # denotes significance from AA 
at the indicated time period, p < 0.001. ND = not detectable. 
 
 
A2P reduces HIF-1α activity and invasive potential more effectively than DHA 
 Since our data demonstrated that incubation with A2P results in significantly higher 
intracellular accumulation of vitamin C compared to DHA over an extended time period, we 
wanted to evaluate the possible therapeutic potential of A2P and DHA by assessing any changes 
in malignant potential during that time. Examination of the ability of 100 µM A2P, AA, or DHA 
to inhibit HIF-1α transcriptional activity at 48 and 72 h in WM9 cells indeed demonstrated 
persistent inhibition of HIF activity following A2P treatment, while DHA treatment proved to be 
ineffective (Fig. 22A-B).  
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Figure 22.  Comparison of vitamin C compounds to decrease HIF-1α transcriptional 
activity over time in WM9 melanoma cells. 
Similar to Fig. 3F, WM9 were transiently transfected with an HIF-1 HRE-luciferase reporter 
vector. Following overnight transfection, cells were treated with the hypoxia-mimetic CoCl2 
(100 µM) with or without 100 µM A2P, AA, or DHA for A) 48 h and B) 72 h. Our findings 
show A2P supplementation significantly attenuates HIF-1 activity up to 72 h. Data was analyzed 
using One-way ANOVA with a Tukey multiple comparison test. Error bars represent SEM, n = 
3. * denotes statistical significance from CoCl2 induced cells p < 0.05. # denotes statistical 
significance from DHA treated cells p < 0.05; ## p < 0.01. Data was normalized as percent of 
control (control = 100 %; not shown). 
 
In order to assess and compare the ability of A2P vs. DHA to decrease the malignant potential of 
metastatic WM9 cells, we conducted 3D tumor spheroid invasion assays. Cells were incubated in 
the presence or absence of A2P or DHA (100 µM) for four days prior to the generation of 
spheroids and throughout spheroid formation. Following seeding and formation of tumor 
spheroids, spheroids were directly imbedded in matrigel matrix (with the addition of 100 µM of 
the appropriate vitamin C) and the migration of invasive cells into the matrix was monitored over 
the next 96 h. Our findings show that A2P effectively prevented the migration and invasion of 
cells, limiting spheroid progression to approximately 3.0 %, while control and DHA 
supplemented cells demonstrated a 20 % and 23 % increase in spheroid diameter respectively 
(Fig. 23A-B). These results further demonstrate the reduced efficacy of using DHA as a potential 
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therapeutic agent to re-establish intracellular AA levels. Cell counts prior to spheroid formation 
following the four day pretreatment of cells confirmed vitamin C treatment did not result in 
altered cell proliferation (data not shown). 
 
Figure 23.  A2P, but not DHA, inhibits the invasive potential of human melanoma. 
WM9 cells were pretreated with or without A2P or DHA (100 µM) for four days prior to the 
generation of tumor spheroids. Following their suspension in matrigel, A) images of the tumor 
spheroids were collected up to 96 h to visualize cell migration/invasion. B) The diameter of the 
expanding tumor spheroids, including the migrating cells, was measured to access the impact of 
A2P or DHA on cancer cell migration/invasion. Our results demonstrate supplementation with 
A2P is capable of limiting the invasive potential of WM9 metastatic melanoma cells. Not 
surprising, DHA was largely ineffective at inhibiting cell migration/invasion. Images are 
representative of multiple experiments. Data was analyzed using Two-way ANOVA with a 
Tukey multiple comparison test. Error bars represent SEM, n = 3. @ denotes statistical 
significance between control and DHA treated cells p < 0.05. * denotes statistical significance 
between control and A2P treated cells p < 0.05; ** p < 0.001; *** p < 0.0001. # denotes 
statistical significance between A2P and DHA treated cells p < 0.05; ## p < 0.0001. 
 
AA mediated regulation of HIF-1 is dependent on SVCT2 activity 
 After confirming that the non-responsiveness of WM9 cells to DHA is not due to the 
absence of GLUT1 expression or function, we wanted to confirm that modulation of HIF activity 
by AA is dependent on SVCT2 activity, resulting in increased intracellular accumulation of 
vitamin C (as AA) rather than unrelated extracellular stimuli triggered by AA supplementation. 
To demonstrate the role of SVCT2 in AA mediated HIF-1 regulation, the activity of SVCT2, a 
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sodium dependent transporter, was functionally inhibited by the replacement of sodium chloride 
(NaCl) with choline chloride (ChCl) in the transport buffer. Since SVCTs are the only 
transporters capable of transporting AA (May, 2011), the impact of sodium deprivation from the 
media would effectively prevent any extracellular transport of reduced vitamin C. To measure 
the impact of sodium removal on AA accumulation, WM9 cells were incubated for 30 min in 
either NaCl or ChCl containing transport buffer with 100 M AA before intracellular vitamin C 
content was determined. Substitution of Na in the transport buffer resulted in complete inhibition 
of vitamin C accumulation in the cells (Fig. 24A). To demonstrate the functional impact of 
SVCT transporter inhibition on AA mediated HIF-1 regulation, cells were pretreated with 
EDHB (750 µM) for 2 h in standard RPMI media to induce HIF-1 before the media was 
exchanged with NaCl or ChCl transport buffer with or without AA (100 µM) for 30 min. As 
determined by western blot, inhibition of SVCT2 function also prevented the AA mediated 
decrease in HIF-1α protein stability (Fig. 24B), demonstrating that the functionality of SVCT2 is 
directly associated with AA accumulation and anticancer activity within these cells. 
 The tumor microenvironment of aggressive malignancies is frequently found to be 
slightly acidic (pH 6.5 – 6.9) (Estrella et al., 2013). Because SVCT2 function can be diminished 
by decreasing pH (Liang et al., 2001), potentially contributing to reduced tumor AA levels, as 
well as presenting a challenge for the implementation of AA therapy, we wanted to examine the 
impact of pH on the ability of AA vs. DHA to be transported across the plasma membrane. To do 
this WM9 cells were pretreated for 30 min with a concentration of AA or DHA (100 µM; 
empirically determined from Fig. 21B) known to inhibit HIF-1α protein stability in a standard 
transport buffer (1 g/L glucose) adjusted to pH 6.5, 7.0, or 7.4. Following pretreatment, buffer 
was exchanged with fresh RPMI containing EDHB (750 µM) for 2 h before cell collection. 
80 
 
Using HIF-1α protein degradation as an indicator for transporter function, western blot analysis 
shows that reduced pH, representative of the tumor microenvironment, did not alter the activity 
of SVCT2 or GLUT1 (Fig. 24C), suggesting that the reduced pH of the microenvironment would 
likely have a negligible impact on the uptake of therapeutic AA or DHA.  
 
Figure 24.  SVCT2 function mediates the regulation of HIF-1α by ascorbic acid. 
A) WM9 cells were incubated with AA (100 µM) for 30 min. in a transport buffer containing 
NaCl (Na) or choline chloride (Ch) before the cells were collected and intracellular AA 
accumulation was measured. Error bars represent SEM, n = 3. ND = not detectable. B) WM9 
cells were incubated with AA for 30 min. in transport buffer containing either NaCl (Na) or 
choline chloride (Ch). Following incubation, buffer was exchanged for fresh RPMI containing 
EDHB (750 µM) for 2 h. Western blot analysis demonstrates that SVCT2 activity is required to 
mediate AA regulation of HIF-1α stability. C) WM9 cells were incubated with AA or DHA for 
30 min. in standard transport buffer containing 1 g/L glucose and adjusted to pH 6.5, 7.0, or 7.4 
to examine the impact of pH on transporter function. After AA or DHA pretreatment, buffer was 
exchanged with RPMI containing EDHB for 2 h as indicated. Using the status of HIF-1α protein 
as a measurement of sufficient vitamin C transporter activity, western blots indicate lower pH 
does not impair the ability of SVCT2 or GLUT1 to increase functional intracellular vitamin C 
content in our cells. Blots are representative of three different experiments each with similar 
results. 
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Inhibition of HIF-1 depends on cofactor function and not antioxidant properties 
Since intracellular AA can function as an enzyme cofactor or as an antioxidant (free 
radical scavenger) we wanted to confirm that the AA associated inhibition of HIF-1 protein 
stability is a result of its HIF hydroxylase (PHD1-3, FIH) cofactor function rather than an 
indirect function of its antioxidant properties. Therefore we examined the protein stability of 
EDHB-induced HIF-1α following short (30 min) or long term (24 h) incubation with increasing 
concentrations (10-500 M) of N-acetyl cysteine (NAC), another common antioxidant. 
Supplementation with NAC failed to reduce HIF-1α protein accumulation at all concentrations 
and time points (Fig. 25A-B) confirming AA mediated decrease of HIF-1 is due to its function 
as a PHD/FIH cofactor and is not the result of its antioxidant properties.  
 
Figure 25.  Ability of NAC to decrease EDHB induced HIF-1α protein stability. 
A) WM9 cells were incubated with EDHB (750 µM) for 2 h before the media was exchanged 
with fresh RPMI containing low concentrations (10 – 100 µM) of NAC for 30 min. before 
nuclear protein extracts were analyzed by western blot. B) WM9 cells were incubated in RPMI 
containing EDHB with or without increasing concentrations (100 – 500 µM) of N-acetyl cysteine 
(NAC) for 24 h. Western blot analysis for both experiments indicates NAC is unable to regulate 
the protein stability of HIF-1α. Blots are representative of biological repeats with similar results. 
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Discussion 
The colonization of malignant melanoma to distant tissues coincides with a dramatic 
decrease in patient survivability (Siegel et al., 2016). One of the defining characteristics of 
metastatic melanoma is aberrant increased expression and activity of the HIF-1 transcription 
factor (Konstantina et al., 2011; Kuphal et al., 2010). Widespread evidence suggests elevated 
HIF activity promotes the acquisition of several cancer hallmarks including, but not limited to, 
rapid tumor invasion, induction of angiogenesis, resistance to cell death, and the procurement of 
classic Warburg metabolism (Courtnay et al., 2015; Greijer and Van Der Wall, 2004; Hanahan 
and Weinberg, 2011; Lu and Kang, 2010; Zimna and Kurpisz, 2015). Several factors may 
contribute to aberrant HIF activity in melanoma including inadequate intratumoral AA, which 
has previously been associated with tumor accumulation of HIF-1α in a variety of different 
malignancies (Kuiper et al., 2014b; Kuiper et al., 2010). Our previous findings demonstrating 
that supplementing metastatic melanoma cells with physiological concentrations of AA 
decreases their malignant potential, suggests that AA deficiency plays a biologically relevant 
role in oncogenesis, and highlights the need to evaluate its efficacy and use in the clinical setting 
to improve patient response and survival. The goal of this study was to evaluate and compare the 
efficacy of AA and DHA supplementation (≤ 0.5 mM) as therapeutic means to promote 
increased intracellular AA; promote AA mediated regulation of aberrant HIF- protein 
stabilization and transcriptional activity and reduce the malignant potential of human melanoma 
cells. 
Circulating plasma and tissue vitamin C is maintained by the dietary ingestion and 
intestinal absorption of AA and/or DHA. Following absorption, enterocytes reduce DHA to AA 
and the pool of intracellular AA is released into the plasma by diffusion or hypothesized volume-
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sensitive anion channels (Lindblad et al., 2013; Wilson, 2002). The rapid reduction of DHA in 
the enterocytes, as well as its relative instability at physiological pH (Fig. 16), results in very low 
levels of plasma DHA (2-5 µM) (Liang et al., 2001), while under the same conditions, AA exists 
as an ascorbate monoanion (Du et al., 2012b) (commonly referred to as AA; 60-80 µM). The 
ability of oral DHA supplementation to treat or prevent scurvy has been vigorously contested for 
decades with some reports showing complete reversal of scurvy symptoms yet others 
demonstrate low vitamin C activity following oral DHA administration (Frikke-Schmidt et al., 
2016; Ogiri et al., 2002; Otsuka et al., 1986; Todhunter et al., 1950). Regardless of the 
contradictory reports, it is likely that any increased vitamin C activity after DHA ingestion is 
derived from elevated plasma AA levels stemming from the reduction of DHA and subsequent 
secretion of AA from the intestinal lumen. This implies that oral DHA supplementation would be 
unlikely to result in elevated plasma DHA levels, thus limiting the use of DHA as a therapeutic 
agent to intravenous administration. Intravenous administration immediately demonstrates a 
disadvantage for any oncology patient prescribed DHA treatment because they will require 
additional medical assistance. Conversely, oral vitamin C supplementation in the form of AA 
would likely be sufficient to restore physiological AA in cancer patients. Therefore, intravenous 
injection of DHA would only be preferred if it provided a significant therapeutic advantage over 
AA. 
To evaluate and compare the efficacy and functional impact of AA vs. DHA 
supplementation as a potential therapeutic option in melanoma, we compared the ability of A2P 
and DHA to decrease the protein stability and accumulation of HIF-1α in WM9 and WM239A 
metastatic melanoma cells. After discovering that DHA was less effective in decreasing HIF-1α 
protein than A2P (Fig. 17), we wanted to evaluate the impact of the various vitamin C 
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compounds on the overall transcriptional activity of HIF-1α in a collection of human melanoma 
cell lines representing various stages of melanoma progression and HIF-1 expression/stability 
(Fig. 18). While AA acts as a cofactor for several enzymes, its impact on PHD and FIH activity 
is particularly important because of its regulation of HIF-1α activity, which is known to 
contribute to oncogenic progression not only in melanoma but other malignancies as well. Our 
data demonstrated all melanoma cells were sensitive to AA supplementation, particularly via 
A2P, while only cell lines with low HIF-1α induction (WM3211 and SbCl2; Fig. 18B-C) were 
significantly responsive to DHA. Alternatively, WM1366 and WM9 cells, representative of 
advanced stage melanoma, were non-responsive to DHA (Fig. 18E-F). 
Other studies in breast cancer, demonstrate a correlation between SVCT2 expression and 
sensitivity to AA treatment (Hong et al., 2013). To elucidate factors that may contribute to the 
differential response of melanoma to AA and DHA, we investigated the prevalence and 
subcellular localization of SVCT2 and GLUT1 protein in our melanoma cell lines since SVCT2 
specifically transports reduced vitamin C (AA), and GLUT1 transports the oxidized form of 
vitamin C (DHA). SVCT2 appeared to be primarily internalized, with limited localization to the 
plasma membrane, which would suggest a limited capacity for AA uptake (Fig. 20B). This 
finding was somewhat unexpected given our previous and current findings following treatment 
of these cells with AA (Miles et al., 2015), yet this is not entirely unreasonable. Previous 
research has found SVCT1 and 2 can localize to various organelle membranes within the cell 
(Munoz-Montesino et al., 2014; Reidling, Subramanian, Dahhan, Sadat, and Said, 2008). The 
exact purpose of intracellular localization is not fully understood, but the possibility of 
extracellular AA promoting the insertion of SVCTs into the plasma membrane of malignant cells 
is yet to be evaluated. Surprisingly, we observed both WM3211 and WM9 cells have similar 
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expression and localization of GLUT1 (Fig. 20A, C), suggesting that other factors govern the 
potential anti-cancer activity of DHA. 
 It has been suggested that overexpression of GLUT transporters would facilitate 
increased uptake of both glucose and DHA by malignant tissue, however the influence of 
glucose competition on DHA transport was not fully considered (Mccarty, 2013). Recent reports 
show the impact of glucose on DHA uptake varies greatly between cell types (Corti et al., 2010). 
Therefore, it was important to evaluate the impact of physiological glucose (1 g/L) on DHA 
transport to determine if it would limit the ability of melanoma cells to utilize DHA to reestablish 
functional intracellular AA. Our data clearly demonstrates physiological glucose concentrations 
drastically decreased the initial uptake of DHA resulting in a nearly 60 % decrease in 
intracellular vitamin C, yielding results comparable to incubation with AA (Fig. 21A). However, 
when we examined the ability of AA and DHA to decrease HIF-1α protein accumulation under 
the same conditions we found AA was more effective (Fig. 21B). Equally significant is the 
absence of intracellular vitamin C following DHA incubation for 24 – 72 h (Table 2). This 
finding suggests that although WM9 cells are capable of initially transporting equimolar 
concentrations of AA and DHA across the plasma membrane (Fig. 21A), they are unable to 
effectively recycle intracellular DHA to AA, resulting in decreased activity likely through the 
irreversible degradation of DHA and loss of AA necessary for downstream functions over an 
extended period of time (Fig. 16). The inability of DHA to be recycled is likely attributed, at 
least in part, to deficiencies in DHA reductase activity or glutathione. The observation that DHA 
is still transported into the cell after treatment with a GLUT1 inhibitor, STF-31, is likely due to 
the presence of GLUT3 protein, which is also known to transport DHA (Rumsey et al., 1997). 
GLUT3 protein expression and function was not extensively examined in this study because of 
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the minimal expression of GLUT3 mRNA compared to GLUT1 in our cell lines (data not 
shown). 
 The inability of WM9 cells to accumulate and maintain vitamin C levels following 
incubation with DHA raises considerable concerns as to whether clinical DHA supplementation 
could increase intracellular AA content sufficiently to promote its cofactor function and 
anticancer activity. To compare the biological significance of DHA vs. A2P supplementation we 
used 3D tumor spheroid invasion assays to evaluate the ability of DHA and A2P to decrease 
invasive potential of WM9 cells. 3D invasion assays were chosen because they more accurately 
model physiological tumor conditions in vitro. Supporting our previous findings in 2D invasion 
chambers (Miles et al., 2015), these assays demonstrate that incubation of WM9 cells with A2P 
significantly inhibits cell migration/invasion; however, DHA supplementation failed to impede 
cell migration/invasion, resulting in spheroid formations nearly identical to non-treated control 
cells (Fig. 23A-B). While our WM9 tumor spheroids do not display single cell projections 
typically associated with an invasive phenotype in 3D culture, the morphogenesis of our 
spheroids are reminiscent of collective cancer cell migration/invasion (Friedl, Locker, Sahai, and 
Segall, 2012). We were able to exclude changes in cell proliferation as the cause of increased or 
decreased spheroid diameter by conducting cell counts following A2P or DHA incubation prior 
to the formation of spheroids (data not shown).  
 While the response to DHA is not solely dependent on the expression and function of 
GLUT1, we sought to investigate the influence of SVCT2 activity on the modulation of HIF-1α 
following AA intervention. In an earlier report, Hong et al. observed SVCT2 expression was an 
indicator of cytotoxicity for high dose (> 1 mM) AA treatment in breast cancer (Hong et al., 
2013). By evaluating the impact of inhibiting the function of SVCT2 on AA mediated HIF-1 
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regulation in WM9 cells, we found the ability of AA to regulate HIF-1α was entirely dependent 
on SVCT2 transporter activity (Fig. 24A-B). Also, our data demonstrated that incubation with 
AA under acidic conditions representative of the tumor microenvironment (pH 6.5) did not 
impede the ability of AA to decrease HIF-1α protein stability, indicating any inhibition of 
SVCT2 function by a pH change did not result in a biologically significant decrease in the ability 
of melanoma cells to accumulate and use AA (Fig. 24C). Lastly, Fig. 25 demonstrated incubation 
with the common antioxidant NAC is unable to decrease the protein stability of HIF-1α, 
providing evidence that regulation of HIF-1 by AA was a result of its function as a PHD/FIH 
cofactor and not a general antioxidant property, supporting the dependence of enzyme function 
on the presence of AA. 
 Previously we have shown that melanoma progression is associated with increasing 
normoxic (aberrant) expression of HIF-1α (Mills et al., 2009) and that supplementing cells with 
physiological concentrations of AA not only decreased HIF activity but also reduced malignant 
properties of metastatic cells (Miles et al., 2015). These studies demonstrate that AA may be a 
beneficial adjuvant therapy for melanoma patients, as well as patients with other types of 
malignancies, particularly those demonstrating elevated HIF activity. Previous studies have 
determined that individuals with plasma AA levels < 28 µM had a 62 % increased likelihood of 
dying from cancer compared to those with AA levels ≥ 74 µM, and that mortality risk decreased 
dose-dependently with increasing plasma AA (Goyal et al., 2013; Loria et al., 2000). While the 
evidence for using AA as a cancer therapy continues to mount, it is speculative as to whether the 
use of DHA, either intravenous or dietary, would provide a therapeutic benefit to cancer patients. 
Most of the dispute surrounding the efficacy of DHA as a therapeutic source for AA involves its 
ability to alleviate scurvy, not cancer. One of the only studies examining the anti-cancer effects 
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of high-dose DHA found that DHA (IC50 = 12.7 – 30 mM) was much less effective than high-
dose AA (IC50 ≈ 4 – 8 mM) in decreasing the viability of several different malignant cell lines 
(Fromberg et al., 2011). However, the cytotoxic mechanism of high dose AA (> 1 mM) is 
dependent on the generation of H2O2 to induce cell death, rather than restoration of its cofactor 
function resulting in the down regulation of HIF activity, making the significance of this 
comparison difficult to interpret. In our present study we clearly demonstrated the improved 
efficacy of low dose AA vs. DHA (≤ 0.5 mM) to decrease invasive potential in metastatic 
melanoma conceivably by increasing intracellular vitamin C content and decreasing HIF activity 
through optimization of PHD/FIH function. The inability of DHA intervention to regulate HIF 
activity, and therefore invasion, is likely attributed to a combination of several factors, 1) the 
insufficient uptake of DHA in the presence of physiological glucose, 2) the failure of metastatic 
melanoma cells to reduce intracellular DHA to AA, possibly due to inefficient DHA reductase 
activity or a high endogenous oxidative burden depleting glutathione, and  3) the rapid and 
spontaneous irreversible degradation of non-recycled DHA within the cell. 
Conclusion 
 These studies provide evidence to suggest that AA supplementation would in fact be 
more effective than DHA as an adjuvant therapy in the treatment of advanced cancer, 
particularly in malignancies such as melanoma, which demonstrate aberrant regulation of HIF-
1. Adequate delivery of intracellular AA is crucial for restoring or augmenting its cofactor 
function for critical enzymes such as the HIF hydroxylases, which regulate the protein stability 
and accumulation, as well as the transcriptional activity of the HIF-1α/HIF-1 transcription factor. 
Human melanoma is collectively sensitive to AA therapy; however in our studies, only early 
stage non-aggressive melanoma is significantly responsive to DHA intervention, while providing 
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little impact in metastatic melanoma which typically requires chemotherapeutic intervention. 
Melanoma cells express the vitamin C transporters necessary for the uptake of both AA and 
DHA; however, in metastatic cells the fact that the initial uptake/transport of DHA across the 
plasma membrane is impeded by the presence of physiological glucose potentially impacts its 
clinical efficacy. This observation, accompanied by the probable degradation of unrecycled 
DHA, likely contributes to the inability of DHA supplementation to increase intracellular 
vitamin C content this leads to ineffective regulation of HIF-1α, ultimately resulting in failure to 
attenuate melanoma cell invasion, in comparison to AA. We also determined that the ability of 
AA to regulate HIF-1α is dependent on SVCT2 activity; however the ability of SVCT2 to 
modify HIF-1α is unaffected by decreasing pH. These findings are clinically relevant when 
considering interventions to restore physiological AA levels in patients diagnosed with advanced 
cancer and highlight the need for further investigation, particularly for clinical trials examining 
the benefit of restoring physiological AA not only in melanoma, but other cancer types as well.  
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CHAPTER 4 
SILENCING HIF-1α INDUCES TET2 EXPRESSION AND AUGMENTS ASCORBIC 
ACID INDUCED 5-HYDROXYMETHYLATION OF DNA IN HUMAN METASTATIC 
MELANOMA CELLS. 
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Abstract 
Expression and function of Ten-eleven translocation (TET) enzymes, which initiate DNA 
demethylation by catalyzing the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine 
(5hmC) on methylated DNA, are frequently lost in malignant tissue. Inactivity of TETs 
ultimately results in lost expression of methylated tumor suppressor genes. Many malignancies, 
including melanoma, also aberrantly overexpress the oncogenic hypoxia inducible factor-1α 
(HIF-1α) transcription factor; however the association between HIF-1 and TET enzyme 
expression is largely uninvestigated. Interestingly, ascorbic acid, a critical cofactor for optimal 
TET enzyme function and normoxic regulation of HIF-1 protein stability, is frequently depleted 
in malignant tissue, and may further contribute to the malignant phenotype. In our studies, we 
found supplementation of WM9 human metastatic melanoma cells with ascorbic acid 
significantly increased 5hmC content, which was abrogated by TET2 knockdown. Moreover, 
knockdown of HIF-1α increased TET2 gene and protein expression, and further augmented 
ascorbic acid-induced TET2 dependent 5-hydroxymethylation in both WM9 and T98G 
glioblastoma cells. Our data provides novel evidence that HIF-1 is involved in regulating TET 
expression and 5hmC status of malignant cells. Furthermore, therapeutic intervention to inhibit 
HIF-1 in conjunction with adjuvant ascorbic acid may promote DNA demethylation and 
reexpression of critical tumor suppressor genes in malignant cells and warrants further 
investigation. 
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Background 
DNA methylation is essential for the regulation of cellular differentiation and 
development. It is now understood that modifications to the epigenome, including aberrant DNA 
methylation, are common in cancer. For years DNA methylation was thought to be an 
irreversible process, managed only by DNA methyltransferase (DNMT) inhibition and DNA 
dilution following replication (Bochtler, Kolano, and Xu, 2017). However, the recently identified 
Ten-eleven translocation (TET1-3) enzymes are now recognized to contribute to demethylation 
by oxidizing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), promoting active 
demethylation and the subsequent excision and replacement with unmodified cytosine in the 
DNA (Huang and Rao, 2014; Rasmussen and Helin, 2016). 
TET enzyme dysfunction was first associated with cancer following the discovery of 
TET1 and numerous TET2 mutations in hematological malignancies. Accumulating evidence 
suggests aberrant TET function may also contribute to several solid malignancies as well. Loss 
of function of multiple TET isoforms by mutation/deletion, reduced protein expression, or 
enzyme inhibition have been identified in clear-cell renal cell carcinoma, colorectal, gastric, 
prostate, liver, lung, and breast cancers, in addition to glioblastoma and melanoma, with the 
latter six malignancies exhibiting a corresponding loss of 5hmC (Huang and Rao, 2014; 
Rasmussen and Helin, 2016). While current evidence suggests decreased TET function and/or 
5hmC are associated with increased tumorigenesis and metastasis in multiple malignancies 
(Chen et al., 2017; Hsu et al., 2012; Song et al., 2013), the consequences of 5hmC loss may be 
most exemplified in melanoma. Primary and metastatic melanomas demonstrate decreased 
expression of TET enzymes, particularly TET2, when compared to non-neoplastic nevi (Lian et 
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al., 2012). Strikingly, the subsequent loss of 5hmC correlates with increasing malignancy and 
poor clinical outcomes, whereas melanomas retaining 5hmC are more typical of lower tumor 
stage (≤ 1) and increased survivability (Gambichler, Sand, and Skrygan, 2013; Lee et al., 2014; 
Lian et al., 2012; Uchiyama et al., 2014). The loss of 5hmC is so significant it has been declared 
an epigenetic hallmark of melanoma (Lian et al., 2012). 
Like all other enzymes in the Fe II/2-oxoglutarate dioxygenase family, TET enzymes 
require a common set of co-substrates and cofactors, including enzyme-bound non-heme ferrous 
iron, 2-oxoglutarate, ascorbic acid, and oxygen (O2) to maintain optimal activity. The 
dependence of TET function on oxygen availability has been suggested to contribute to 5hmC 
loss within dense hypoxic tumors; however, other environments with equivalent low 
oxygenation, such as those surrounding embryonic tissues and the bone marrow, maintain high 
TET activity (Ito et al., 2010; Tahiliani et al., 2009), suggesting other factors related to 
pathological hypoxia may contribute to the regulation of TET function within malignant cells. 
While the impact of hypoxia on TET function has been previously described (Thienpont et al., 
2016), the influence of stabilized Hypoxia Inducible Factor-1 (HIF-1) transcription factor 
remains largely under investigated. In malignant tissue, including melanoma (Konstantina et al., 
2011), HIF-1α, the subunit that confers HIF-1 transcription factor activity, is often aberrantly 
overexpressed (Mills et al., 2009), contributing to the expression of genes that facilitate an 
aggressive malignant phenotype similar to melanomas presenting with low 5hmC content. The 
notable occurrence of HIF-1α overexpression and loss of 5hmC in high grade melanomas may 
suggest a relationship between both pathways that contributes to the progression of melanoma. 
Interestingly, both pathways are regulated by Fe II/2-oxoglutarate dioxygenase enzymes, which 
require ascorbic acid as a cofactor. Accordingly, ascorbic acid supplementation has been shown 
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to inhibit HIF-1α accumulation and stimulate increased 5hmC content (Blaschke et al., 2013; 
Miles et al., 2015), suggesting a possible dual benefit for ascorbic acid therapy in patients with 
advanced melanoma. The objective of this study was to investigate the influence of HIF-1 on 
TET enzyme expression and function and its subsequent impact on the capacity of ascorbic acid 
to modulate the 5hmC content through enhanced TET activity in metastatic melanoma. To 
examine the effects of HIF-1 on TET, independently of hypoxia, we conducted in vitro studies 
using WM9 human metastatic melanoma cells which have been demonstrated to aberrantly 
stabilize and accumulate elevated levels of HIF-1α protein under normoxic conditions (Mills et 
al., 2009). Here we report for the first time, evidence that HIF-1α negatively regulates TET2 
gene and protein expression and may contribute to the oncogenic epigenetic landscape in 
malignant tissue.  
 
Materials and methods 
Cell culture and reagents 
WM9 human metastatic melanoma and T98G human glioblastoma cells were incubated 
in a humidified incubator at 5 % CO2 / 95 % air at 37 °C while cultured in standard RPMI 1640 
media (Lonza) supplemented with 10 % fetal bovine serum (FBS) and 0.5 % 
penicillin/streptomycin. All cell treatments with ascorbic acid were done using 100 M ascorbate 
2-phosphate (A2P) for the times indicated. A2P is an oxidation resistant analog of ascorbic acid 
with increased stability in cell culture (Fischer and Miles, 2017). WM9 cells were a generous gift 
from Dr. Meenhard Herlyn at the Wistar Institute (University of Pennsylvania). L-Ascorbic acid 
2-phosphate sesquimagnesium salt hydrate (A2P) and cobalt chloride (CoCl2) were purchased 
from Sigma. 
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Reverse transcription and qPCR 
Total RNA was isolated from cells using an All prep DNA/RNA kit (Qiagen) following 
the manufacturers protocol. mRNA quality and quantity was assessed spectrophotometrically 
using a NanoDrop 200 UV/Vis spectrophotometer. cDNA was synthesized from total mRNA 
using the Advantage RT-for-PCR kit (Clonetech Laboratories) following the manufacturers 
protocol. Following the generation of standard curves, Taqman Gene expression assays were 
conducted using primer/probe sets for TET1, 2, and 3 (hs00286756_m1; hs00325999_m1; 
hs00379125_m1; Applied Biosystems) on a QuantStudio® 3 Real-Time PCR system (Applied 
Biosystems). Experiments were run in triplicate and data normalized to 18S mRNA expression 
(Cttarget – Ct18S). 
Western blots 
Nuclear protein extracts were prepared using a NePER Nuclear and Cytoplasmic 
Extraction Kit (Pierce) following the manufacturers protocol. Protein lysates were separated by 
SDS-PAGE on 4-20 % MP-TGX precast polyacrylamide gels (BioRad) and transferred to 
nitrocellulose using BioRad MINIProtean3 system. Membranes were immunoblotted with 
antibodies against TET1 (1:250; Santa Cruz), TET2 (1:5000; Novus), TET3 (1:1000; EMD 
Millipore), and HIF-1α (1 µg/mL; R&D Systems) overnight at 4C. Equal lane loading was 
accessed by probing for Lamin B1 (1:1000; CST) or total protein using a MemCode™ 
Reversible Protein Stain Kit (Thermo Scientific). Following secondary incubation, blots were 
visualized using an enhanced chemiluminescence detection kit (ECL Prime; GE Healthcare) and 
imaged on a Fotodyne imaging system (Fotodyne Technologies). Densitometry analysis was 
done using ImageJ v 1.50. All blots are representative of three individual experiments. 
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DNA dot blot 
Following cell treatment, DNA dot blots were completed using a 96-well Dot Blot 
apparatus (Biorad). Briefly, total DNA was isolated from collected cells using an All prep 
DNA/RNA kit (Qiagen) according to manufacturer’s protocol and assessed 
spectrophotometrically using a NanoDrop 200 UV/Vis spectrophotometer. DNA was denatured 
by heating to 99 °C for 10 min and diluted to desired concentrations in 2 X SSC buffer (see 
below) immediately preceding experiments. Nitrocellulose membranes were presoaked in 20 X 
SSC buffer (3 M NaCl, 0.3 M sodium citrate, pH 7.0) prior to apparatus assembly and sample 
loading. After drying at 80 °C for 2 h, membranes were blocked in 5 % milk for 1 h at RT and 
incubated overnight in an anti-5hmC antibody (1:1000; Zymo Research). Following secondary 
incubation, blots were visualized using an enhanced chemiluminescence detection kit (ECL 
Prime; GE Healthcare) and imaged on a Fotodyne imaging system (Fotodyne Technologies). 
Total DNA loading was determined by methylene blue staining and used to normalize dot blots 
for densitometry analysis (ImageJ v 1.50g). All blots are representative of three individual 
experiments.  
Small interfering RNA (siRNA) transfection 
Cells were transfected as previously described (Miles et al., 2015). Briefly, cells were 
transfected at time of seeding with 10 nM non-targeting control siRNA, HIF-1α siGENOME 
SMARTpool siRNA, or 20 nM TET2 siGENOME SMARTpool siRNA (GE Dharmacon) using 
Lipofectamine RNAimax in standard RPMI media following manufactures protocol. 1.5X105 
cells were seeded into 35 mm plates with a fresh media change after attachment. Cells were 
collected for analysis 48 h after transfection. 
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Statistical analysis 
Data was analyzed using GraphPad Prism 7 software (version 7.03; GraphPad Software 
Inc.). Statistical significance was determined by One-way or Two-way ANOVA followed by 
Tukey’s multiple comparison tests as appropriate. Three individual trials were performed for 
each experiment and data represented as ± SEM. p < 0.05 was considered statistically significant. 
Specific p values are indicated in figure legends.  
Results 
Ascorbic acid augments TET activity and increases 5hmC in melanoma 
 Published reports have indicated that decreased expression and function of TET enzymes 
inhibits 5hmC levels in malignant cells (Huang and Rao, 2014; Rasmussen and Helin, 2016). 
Our initial experiments surveyed the expression of TET isoforms in WM9 metastatic melanoma 
cells by qPCR and western blot. All three TET isoforms appear to be equally expressed at the 
gene level (Fig. 26A). Furthermore, all three isoforms also appear to be expressed at the protein 
level (Fig. 26B) in these cells. To confirm that the TET proteins expressed in these cells have 
functional activity, we examined the ability of ascorbic acid, a known critical TET enzyme 
cofactor, to promote the formation of 5hmC over time (24 – 72 h). In agreement with previous 
findings (Gustafson et al., 2015), we found that supplementation of cells with 100 m A2P, 
which represents physiological levels of ascorbate (Du, Cullen, and Buettner, 2012a; Fischer and 
Miles, 2017a; Miles et al., 2015), significantly increased global 5hmC levels in our cells (Fig. 
26C-D). We also observed that maintaining cells continuously in A2P for three weeks resulted in 
even greater 5hmC content, showing 5-fold higher 5hmC levels than non-treated controls and 2 
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fold higher than shorter time point (24-72hr) treatments of standard cultured cells with A2P (Fig. 
26C-D).  
 
Figure 26.  Ascorbic acid increases global 5hmC content in WM9 metastatic melanoma 
cells. A) mRNA expression of TET1-3 using qualitative real-time PCR (qPCR) and B) protein 
expression by western blot. Protein expression was examined within the same lane. Total protein 
loading for lane visualized using protein stain. C) WM9 cells were incubated with A2P (100 µM) 
for 24 – 72 h before global 5hmC content analyzed by DNA dot blot. 5hmC content was also 
accessed in cells maintained in A2P (100 µM; changed every 48 h) for three weeks. D) 
Densitometry of DNA dot blots. Data was analyzed by One-way ANOVA with a Tukey’s 
multiple comparisons test. Error bars represent SEM, n = 3. * denotes statistical significances 
from control, p < 0.05; ** p < 0.001. ns = not significant. 
 
Silencing of HIF-1α increases 5hmC by promoting increased TET2 expression 
 Extensive literature evidence suggests 5hmC content in melanoma is primarily regulated 
by TET2 (Gambichler et al., 2013; Lee et al., 2014; Lian et al., 2012). To validate the role of 
TET2 as a principal contributor to the generation of 5hmC in WM9 metastatic melanoma cells, 
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and to determine its suitability as a target to evaluate the potential regulation of TET enzymes by 
HIF-1, we first examined global 5hmC content by DNA dot blot analysis following siRNA 
knockdown of TET2. Silencing of TET2 alone resulted in a marked decrease in 5hmC levels 
(Fig. 27A), demonstrating that the TET2 isoform notably contributes to the epigenetic landscape 
of DNA in these cells. Since aberrantly elevated expression of HIF-1 and reduced 5hmC levels 
appear concurrently in multiple types of malignancies, including melanoma, we wanted to 
evaluate whether HIF-1 contributes to the “hallmark” 5hmC profile seen in melanoma via 
regulation of TET expression and/or activity. To do this we examined mRNA and protein 
expression of TET2 following siRNA knockdown of HIF-1. We found that silencing of HIF-1α 
significantly increased both TET2 gene and protein expression (Fig. 27B-D). Additionally, 
treatment with 100 M A2P did not appear to alter the gene or protein level of TET2 (Fig. 27B-
D) suggesting that the modulation of 5hmC by ascorbic acid is due solely to its function as an 
enzymatic cofactor of TET2. 
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Figure 27.  Silencing of HIF-1α increases TET2 mRNA and protein expression in WM9 
cells.  A) Global 5hmC levels were evaluated by DNA dot blot following siRNA knockdown of 
TET2. B) TET2 mRNA expression was evaluated by qPCR and C) protein expression by 
western blot following siRNA knockdown of HIF-1α and incubation with or without A2P (100 
µM). D) Densitometry data for western blot. Data was analyzed by Two-way ANOVA with a 
Tukey’s multiple comparisons test. Error bars represent SEM, n = 3. * denotes statistical 
significance from non-treated sicont, p < 0.05; ** p < 0.01; *** p < 0.001. # denotes statistical 
significance from A2P treated sicont, p < 0.05; ## p < 0.01; ### p < 0.001. 
 
 To further assess the roles of ascorbic acid and HIF-1α on TET function we examined 
5hmC content of WM9 cells following siRNA knockdown of TET2 or HIF-1α in the presence or 
absence of A2P (100 µM). To validate that the increase in 5hmC following A2P supplementation 
(Fig. 26C-D) is in fact due to its function as a TET2 cofactor, TET2 siRNA knockdown cells 
were treated with or without 100 M A2P, and global 5hmC was measured by DNA dot blot. 
Knockdown of TET2 not only eliminated basal 5hmC, but also completely abrogated the 
response to A2P, showing no induction of 5hmC levels by A2P (Fig. 28A-B). Remarkably, while 
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silencing of HIF-1α significantly increased TET2 protein, it did not significantly increase 5hmC 
levels (Fig. 28A-B). However, knockdown of HIF-1 in addition to A2P supplementation 
resulted in global 5hmC content approximately 3.3 times higher than A2P treatment alone (Fig. 
28A-B). This data suggests that while TET2 expression may be regulated in part by HIF-1, 
global 5hmC content is dependent on TET2 enzyme activity, which is significantly augmented 
by the presence of ascorbic acid. To determine if these findings were specific to melanoma, we 
repeated this experiment using T98G glioblastoma cell line (also known to accumulate normoxic 
HIF-1α protein (Jensen, Ragel, Whang, and Gillespie, 2006)) with comparable results (Fig. 28C-
D), further supporting a role for HIF-1 in modulating the epigenetic landscape by regulation of 
TET2. 
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Figure 28.  Silencing HIF-1α significantly increases ascorbic acid induced 5hmC content in 
melanoma and glioblastoma cells. 
A) DNA dot blots of 5hmC content were used to evaluate the effects of silencing TET2 and HIF-
1α gene expression on A2P supplemented WM9 cells. B) Densitometry data for DNA dot blot. C 
and D) Experiment was repeated using T98G glioblastoma cells with comparable results. Data 
was analyzed by Two-way ANOVA with a Tukey’s multiple comparisons test. Error bars 
represent SEM, n = 3. * denotes statistical significance from non-treated sicont, p < 0.0001. # 
denotes statistical significance from A2P treated sicont, p < 0.001; ## p < 0.0001. 
 
Discussion 
 The discovery of TET enzymes less than 10 years ago has led to a richer understanding of 
cellular DNA methylation control and the importance of epigenetic regulation in various disease 
states including cancer. Aberrant hypermethylation is commonly observed within CpG islands of 
tumor suppressor promoters, allowing silencing of these genes, and supporting malignant 
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transformation and progression. TET enzymes promote DNA demethylation by inducing the 
formation of 5hmC from 5mC, which is then further oxidized by TET enzymes to 5-
formylcytosine and 5-carboxylcytosine before being excised and replaced with unmodified 
cytosine by DNA repair enzymes (Huang and Rao, 2014; Rasmussen and Helin, 2016). 
Currently, TET1-3 are the only enzymes known to induce hydroxylation of 5mC thus (Ficz and 
Gribben, 2014), low levels of 5hmC correspond with impaired TET expression or function. Loss 
of 5hmC correlates with advanced cancer and poor survival in numerous malignancies including 
melanoma (Chen et al., 2017; Uchiyama et al., 2014), suggesting treatments to improve TET 
activity and increase 5hmC content may be a valuable treatment strategy. 
 As the significance of 5hmC in both normal and malignant tissue becomes more 
apparent, the need to understand its regulation, particularly through the activity and regulation of 
TET enzymes, is paramount. While evidence implicates oxygen availability as a major regulator 
of TET activity, kinetic studies have revealed TET1 and 2 have a Km value for O2 of 0.31 and 
0.53 % respectively (Thienpont et al., 2016), which is significantly lower than the reported 1.4 % 
median oxygen content typical of solid malignancies (Mckeown, 2014). These studies suggest 
complete inhibition of TET function may not actually occur during pathological hypoxia (0.3 – 
4.2 % O2 depending on tumor type) (Mckeown, 2014). However, prolyl hydroxylase 2 (PHD2), 
the oxygen-sensing enzyme that primarily regulates the stability and accumulation of HIF-1α, 
has a Km for O2 that is about eight times higher than TET1 and 2 (Laukka et al., 2016) 
suggesting intratumoral hypoxia would not be limiting for TET activity, but would be inhibitory 
to PHD function and promote the accumulation of HIF-1. 
The possible influence of elevated or aberrantly stabilized HIF-1 on TET function has 
remained largely uninvestigated, although a recent report has found evidence that TET1 may be 
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necessary to elicit a full hypoxic response in neuroblastoma cells by demethylating the promoters 
of hypoxic response genes (Mariani et al., 2014), warranting further examination of the 
interactions between HIF-1 and TET enzymes in malignant cells. In the present study for the first 
time, we provide evidence for a novel interaction between HIF-1 and TET2 expression in 
human melanoma and glioblastoma. Remarkably, we found that silencing gene expression of 
HIF-1α in WM9 metastatic melanoma cells, which are known to aberrantly stabilize and 
accumulate high levels of HIF-1α protein (Mills et al., 2009) even under normoxic conditions, 
significantly increased both the mRNA and protein expression of TET2 (Fig. 27B-D). Elevated 
TET2 expression via HIF-1α inhibition, in conjunction with A2P supplementation (which 
augments the activity of both TET and PHD enzymes), significantly increased global 5hmC 
content in metastatic melanoma as well as glioblastoma cells (Fig. 28). Given the frequency of 
malignant tissues which express both elevated HIF-1 expression and diminished 5hmC levels, 
our data suggests that regulation of TET2 expression by HIF-1 may be prevalent across 
multiple cancer types and impact the malignant potential of those tissues. 
 Widespread evidence indicates accumulation and transcriptional activation of HIF-1 
drive the progression of malignant melanoma (Zbytek et al., 2013). Concurrently, advanced 
melanomas also present with low levels of 5hmC (Gambichler et al., 2013; Lee et al., 2014; Lian 
et al., 2012; Uchiyama et al., 2014). In the current study, we demonstrated that silencing of HIF-
1α in metastatic melanoma cells with aberrant normoxic HIF-1 activity not only increased the 
expression of TET2 mRNA and protein, but also significantly increased global 5hmC content 
when combined with A2P compared to cells treated with A2P alone. While further investigation 
is required, our data provides novel evidence that high aberrant HIF-1 activity may play a role 
in diminishing 5hmC content, independent of oxygen tension, through inhibition of TET2 
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expression. Loss of TET2 may be caused by the expression of a yet unidentified HIF-1-
dependent TET2 gene repressor or possibly the direct binding of the HIF-1 transcription factor 
may prevent TET2 transcription. In our studies, silencing of HIF-1α had no effect on protein 
expression of TET1 or TET3 (data not shown). Intriguingly, a specific decrease in TET2 
expression within advanced melanomas has been observed (Gambichler et al., 2013; Lian et al., 
2012). While studies have also shown advanced melanomas frequently accumulate HIF-1, 
studies have not investigated a possible association between elevated HIF-1α expression and low 
TET2 expression. Published studies have however demonstrated that overexpression of TET2 
resulted in increased 5hmC levels, decreased melanoma cell invasion, and reduced tumor size in 
murine models compared to a mutant TET2 vector (Lian et al., 2012), highlighting the 
significance of restoring TET2 expression/activity in malignant cells. These studies suggest a 
combination of HIF-1 inhibition in conjunction with adjuvant ascorbic acid therapy could 
prove beneficial in melanoma patients by promoting DNA demethylation of tumor suppressor 
genes. 
  
106 
 
CHAPTER 5 
CONCLUSION 
 
 Dating back to the early 1950’s, oncologists began to speculate the existence of a 
relationship between AA status in humans and malignant disease when a study found that plasma 
AA levels in patients with uterine, gastrointestinal and breast cancer were significantly lower 
than plasma levels in healthy individuals (Bodansky et al., 1952). In 1959, Dr. W.J. McCormick 
postulated that the deterioration of collagen surrounding carcinomas, which would likely 
contribute to malignant invasion and metastasis, may be caused by a nutrient deficiency and 
suggested vitamin C as the primary candidate (McCormick, 1959). Strikingly, besides knowing 
AA is needed to prevent scurvy, only minimal advancements in understanding the role of AA in 
human physiology had been made by the end of the twentieth century. In fact, SVCT1 and 2, the 
only transporters known to carry AA across the cell membrane, were not identified and cloned 
until 1999 in rats (May, 2011; Tsukaguchi et al., 1999), underscoring the slow progression of 
AA research.  
 Today, much more is known about the metabolism and the importance of AA for overall 
wellbeing. Possibly the greatest advancement in vitamin C research is the understanding that AA 
is an essential cofactor for the Fe II/2-oxoglutarate dioxygenase superfamily. Aberrant function 
of many enzymes within the superfamily, including the HIF hydroxylases and TET enzymes, are 
thought to contribute to malignant development and progression (Lian et al., 2012; Zhong et al., 
1999). Unfortunately, inadequate intracellular AA, which is not uncommon for those diagnosed 
with cancer (Huijskens et al., 2016; Mikirova et al., 2013; Schleich et al., 2013), can impair the 
activity of these enzymes and potentially propagate aggressive malignancies. 
 Melanoma is the deadliest form of skin cancer and is attributed to 75 % of skin cancer 
deaths (Siegel et al., 2016). While primary melanomas can be easily treated, there are few 
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treatment options for those with metastatic disease. Therapeutic treatment of metastatic 
melanoma frequently results in acquired resistance, thus the discovery of new and adjuvant 
therapies is necessary to improve disease prognosis. Melanoma is also one of many cancer types 
that has been observed to be associated with an AA depletion in patients (Schleich et al., 2013). 
Interestingly, advanced melanomas frequently exhibit aberrant overactivation of HIF-1 and the 
loss of 5hmC (Konstantina et al., 2011; Lian et al., 2012), both of which can be explained by 
diminished activity of HIF hydroxylases and TET enzymes due to inadequate AA. In these 
studies, we sought to determine if supplementation of human melanoma, particularly metastatic 
melanoma, with physiological levels of AA could decrease the malignant potential of cells by 
inhibiting the aberrant accumulation/activation of HIF-1α and increasing 5hmC content under 
normoxic conditions by augmenting the function of HIF hydroxylases and TET enzymes 
respectively.  
 Throughout chapters 2 and 3 we examine the ability of different forms of vitamin C (AA, 
A2P, DHA) to inhibit hypoxia mimetic induced and normoxic HIF-1α protein accumulation and 
transcriptional activity using multiple melanoma cell lines. In our findings, supplementation of 
cells with both AA and A2P was able to consistently decrease HIF-1α accumulation and activity 
across multiple cell lines, although A2P was more effective in most cells (Fig. 7-12, 18, 22). The 
ability of AA to reduce HIF-1 protein accumulation and activity is most likely due to its 
function as a cofactor and not an anti-oxidant, since treatment with NAC was unable to inhibit 
HIF-1α protein accumulation (Fig. 25). Incubation of WM9 cells with 100 µM AA or A2P for 24 
– 72 h results in significantly higher total intracellular vitamin C content when cells were 
supplemented with A2P (Table 2). Differences in vitamin C content is likely due to the increased 
stability of A2P over AA. Under cell culture conditions, AA is rapidly auto-oxidized, likely due 
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to high oxygen content and components of culture media such as free unbound iron. Therefore, 
A2P is frequently used for in vitro experiments because its stability in a cell culture system more 
accurately represents AA in physiological conditions. This rationale provides a sensible 
explanation for the improved performance of A2P over AA in cell culture conditions. 
 In a recent hypothesis, it has been speculated that treatment of cells with DHA may be a 
better therapeutic option than AA for advanced cancers (Mccarty, 2013). In these cancers, 
alterations to energy metabolism, frequently caused by overactive oncogenes, can increase the 
expression of GLUT1, one of the transporters responsible for DHA uptake (Courtnay et al., 
2015; Mccarty, 2013). Overexpression of GLUT1 may promote increased uptake of DHA by 
cancer cells, resulting in a higher intracellular AA content to be used either as an antioxidant or 
enzyme cofactor following intracellular reduction of DHA to AA in the cytoplasm. Differences 
in intracellular AA accumulation are possible because AA and DHA enter the cell via two 
different transport systems (SVCTs or GLUTs) (Lindblad et al., 2013). Therefore, we also 
investigated the ability of DHA to decrease HIF-1α accumulation and activity compared AA or 
A2P. Our studies found incubation of WM9 cells with DHA along with physiological glucose 
concentrations (1 g/L) resulted in the rapid depletion of intracellular vitamin C in as little as 24 h 
(Table 1), even though vitamin C content was similar after a 30 min incubation of AA or DHA 
(Fig. 21). Rapid loss of intracellular vitamin C following DHA incubation may be caused by the 
inability of WM9 cells to reduce and recycle DHA to AA and may be caused by a high 
endogenous oxidative burden or deficiencies of DHA reductases. Regardless, given that DHA is 
relatively unstable at a physiological pH (Linster and Van Schaftingen, 2007), inhibition of DHA 
recycling would likely result in the degradation of DHA into metabolites that are excreted from 
the cell (Fig. 16). Not surprisingly, HIF-1α activity of most melanoma cell lines was not 
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significantly decreased following supplementation with DHA (Fig. 17, 18, 22). This data 
suggests elevated GLUT1 expression in malignant melanoma cannot significantly increase DHA 
uptake to an extent to overcome competition with glucose uptake and inefficient DHA recycling, 
limiting DHA’s usefulness as an adjuvant therapy.  
The ability of physiological AA to decrease HIF-1α activity is significant because HIF-1 
is known to contribute to the acquisition of multiple cancer hallmarks (Courtnay et al., 2015; 
Hanahan and Weinberg, 2011; Lu and Kang, 2010; Zimna and Kurpisz, 2015). Because of our 
success using AA to restore activity of the HIF hydroxylases, we wanted to assess its ability to 
augment the function of other 2-OG dioxygenases that are relevant to cancer. Hence in chapter 4, 
we choose to investigate TET enzyme activity following supplementation with A2P. TET 
enzymes are able to facilitate demethylation of gene promoters by oxidizing 5mC to 5hmC, 
commencing a series of reactions ending with cytosine demethylation (Huang and Rao, 2014; Ito 
et al., 2011). Reduced 5hmC content has been linked to an increased malignant phenotype and 
poor patient prognosis in several cancers (Chen et al., 2017); however, it is most prominent in 
melanoma where low 5hmC has been described as an epigenetic hallmark (Lian et al., 2012). In 
our studies, supplementation of WM9 cells with 100 µM A2P dramatically increased global 
5hmC content as evident by DNA dot blots (Fig. 26). Knockdown of TET2 using siRNA 
prevented A2P-dependent generation of 5hmC, confirming TET2 in our cells was the primary 
enzyme regulating 5hmC status (Fig. 27). Surprisingly, we found that silencing HIF-1α using 
siRNA increased TET2 gene and protein expression (Fig. 27). While HIF-1α knockdown alone 
was unable to significantly increase 5hmC content in cells via elevated TET2, the addition of 
A2P (100µM) drastically and significantly increased global 5hmC content in WM9 and T98G 
cells (Fig. 28). Increased 5hmC content is undoubtedly due to the augmented activity of elevated 
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TET2 protein. This finding was novel; therefore, a mechanism explaining how the absence of 
HIF-1α was able to increase TET2 expression is unknown at this time. However, I can speculate 
that the HIF-1 transcription factor may either enhance transcription of a TET2 gene repressor or 
direct binding of HIF-1 to the genome may inhibit TET2 transcription. Regardless of the 
mechanism, these findings provide exciting evidence that HIF-1 may modify DNA methylation 
in malignant cells, particularly in melanoma. This evidence may suggest elevated HIF-1 activity 
and loss of 5hmC, eventually contributing to hypermethylation and silencing of tumor 
suppressors, may not be independent, but instead sequential events that are initiated by HIF-1.  
Finally and most significantly, we have demonstrated that supplementation with A2P was 
capable of significantly decreasing the invasive potential of WM9 cells as determined by 
transwell matrigel invasion assays (Fig. 14). Likewise, A2P also inhibited anchorage 
independent growth of WM9 cells (Fig. 15). Our investigation into which form of vitamin C 
(A2P or DHA) would be more effective in preventing invasion of WM9 tumor spheroids found 
once again A2P decreased invasion while DHA had little to no effect (Fig. 23).  
The canonical loss of 2-OG dioxygenase activity, such as HIF hydroxylases, occurs due 
to the lack of O2. Here, we choose to investigate changes in the hydroxylation of 2-OG 
dioxygenase substrates under aberrant normoxic conditions as to better isolate and understand 
the contribution of AA on dioxygenase function. Previous studies examining hypoxic cell 
cultures observed little to no increase in PHD hydroxylase activity follow AA supplementation, 
likely due to insufficient oxygenation to allow enzyme function, although this is not the case for 
all cells types (Kuiper et al., 2014). Our investigation of WM9 and WM239A cells under 
hypoxic conditions (1.5 % O2) found that 100 µM A2P was unable to decrease protein 
accumulation of HIF-1α; however total transcriptional activity, mediated by FIH, was decreased 
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by approximately 20 % in both cells lines. The biological relevance of this finding was not 
assessed (unpublished observation) but warrants future investigation. While physiological AA 
therapy may not inhibit canonical accumulation of HIF-1α within hypoxic tumor tissue, it may 
still be effective in preventing metastasis by inhibiting HIF activity of invasive cells that enter 
the circulation, and are under normoxic conditions. Metastasis prevention may be possible 
because aberrant activation of HIF-1 influences gene expression that promotes systemic 
dissemination, extravasation, and colonization (Lu and Kang, 2010). Additionally, not all 2-OG 
dioxygenases are as sensitive to hypoxia as the HIF hydroxylases. In fact, the TET enzymes have 
an approximately eight times higher affinity for O2 than PHD2, suggesting TET activity or other 
2-OG dioxygenases may be augmented by AA supplementation in both hypoxic and non-
hypoxic tissues, possibly providing continual anti-cancer activity in all tissues. 
In our studies, we focused on the ability of AA to act as a cofactor for HIF hydroxylase 
and TET enzymes. However, it must be recognized that AA is a cofactor for all enzymes within 
the 2-OG dioxygenase superfamily. There are several other members within the superfamily 
whose dysfunction can contribute to malignant transformation and progression which may be 
alleviated by restoring physiological levels of AA (Kuiper and Vissers, 2014c). Therefore, 
decreased malignant potential of our cells may not exclusively be a result of promoting proper 
HIF hydroxylase and TET enzyme activity, but may be caused from enhancing activity of 
multiple 2-OG dioxygenases. To evaluate the role of additional cancer related 2-OG 
dioxygenases, such as histone demethylases and carnitine biosynthesis enzymes, similar 
experiments, as described in this work, could be conducted by isolating the prospective pathways 
and examining the hydroxylation status of affiliated substrates in response to AA. The most 
interesting finding in our study is the novel interaction between HIF-1α and TET2 gene and 
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protein expression. Since there is no previous literature documenting a connection between HIF-
1α and TET2, extensive in vitro investigations are needed to further elucidate the extent and 
impact of this relationship. These investigations would include establishing the mechanism 
through which silencing HIF-1α increases TET2 expression and determine whether 
overexpression of HIF-1α could facilitate a reciprocal response. While a global increase in DNA 
5hmC content should ensure DNA demethylation, methylation specific PCR including promoter 
sequencing and gene specific reverse transcription-PCR or RNA sequencing should be evaluated 
to confirm gene demethylation and reexpression in response to AA.  
The studies presented herein strongly support the ability of physiological concentrations 
of AA to reduce malignant properties, particularly in melanoma, is based in part on its ability to 
support HIF hydroxylase and TET enzyme activity. This work justifies the need for future 
investigations to evaluate the possible anti-cancer effects of AA through augmenting the function 
of other 2-OG dioxygenases. The conceivable simplicity of using AA as an adjuvant anti-cancer 
therapy cannot be overstated. Currently, most researchers and clinicians conducting vitamin C 
cancer research are investigating the cytotoxic effects of mega dose (> 1 mM) intravenous 
administration of AA as a cancer therapy. Here we have provided evidence that restoring healthy 
physiological levels of AA to patients could in-fact decrease the malignancy of their disease. 
Physiological levels could easily be achieved by oral supplementation or dietary changes with 
careful monitoring by a patient’s primary care physician. These changes may not only be 
physiologically advantageous, but also encourage emotional and mental health as well. 
Frequently, oncology patients suffer from harmful feelings of helplessness and defeat (Van 
Laarhoven et al., 2011). Prescribing specific dietary changes and supplements can allow patients 
to take back a certain degree of control in their lives and promote emotional well-being. AA 
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supplementation may also be valuable as a preventive cancer treatment to inhibit transformation 
events. Shockingly, measurement of plasma AA is not a part of routine laboratory screenings for 
oncology or primary care patients, meaning most individuals and their physicians do not have a 
known measurement of their plasma AA levels. This lack of screening underscores the wide-
ranging underappreciation for the importance of AA in the maintenance of normal cellular 
function and homeostasis. 
As more information related to the cofactor function of AA is discovered, the next logical 
step is to investigate the importance of AA cofactor functions in vivo and in human trials. 
However, vitamin C research has potential limitations and pitfalls that if not recognized by 
investigators could present challenges not only in designing and conducting experiments but also 
in interpreting their results. To date, a vast amount of cancer research has been done using cell 
lines (primary or transformed) derived from a wide range of cancers. It is important to note that 
most commercially available cell culture media and FBS commonly used for these in vitro 
studies are devoid of AA (Michels and Frei, 2013). The lack of AA may be particularly 
worrisome for established cell lines that have likely been cultured without AA since their initial 
isolation. Cell lines can survive without AA because it is not essential for growth and division, 
and thus cells have conceivably adapted to life without AA. While AA is necessary for optimal 
2-OG dioxygenase function, it is not needed to directly facilitate hydroxylation of substrates, but 
instead to reduce enzyme associated Fe3+ to Fe2+ when electron transfer becomes uncoupled 
during the hydroxylation reaction (Kuiper and Vissers, 2014c). It is speculated that cell lines 
have developed increased protein turnover of 2-OG dioxygenases to ensure enzyme activity 
without AA (Michels and Frei, 2013). The most common animal models used for in vivo cancer 
research are mice and rats. Unfortunately, because mice and rats are capable of synthesizing AA, 
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it may make it difficult to extrapolate information that can be applied to human physiology. 
More recently, investigators conducting in vivo vitamin C research have used GULO -/- 
knockout mice. Lacking the enzyme L-gulonolactone oxidase, these mice are similarly 
dependent on vitamin C consumption for survival. However, even in these models, intestinal 
transport (uptake) of AA and DHA may still be differently regulated presumably because mice 
are not normally dependent on intestinal absorption of vitamin C via SVCT1 and GLUTs as in 
humans (Michels and Frei, 2013). Currently, the degree by which gut absorption of AA differs 
between mice and humans is unknown. Therefore, study models that lack endogenous AA 
synthesis, such as guinea pigs, should be preferred particularly for studies involving oral 
administration of vitamin C. In clinical research trials, there is not a standard procedure for the 
collection and determination of AA content in plasma and tissues. Different vacutainers and 
anticoagulants have been shown to affect the stability of AA in various samples (Lykkesfeldt, 
2012). In addition, exposure to heat and light accelerates AA oxidation to DHA as well as DHA 
degradation (Michels and Frei, 2013), making it difficult to accurately quantitate AA levels in 
plasma or extracted from tissue samples. 
Although there are limitations to vitamin C research, that does not mean it is not 
valuable. However, it is imperative that investigators are aware of these challenges when 
designing studies and more importantly when analyzing results. As previously stated, 
investigations into the usefulness of AA as a cancer therapy have been mired in controversy for 
decades. Yet, the conflicting results of past studies may simply be caused by misinterpretation of 
data, stemming from the lack of vitamin C knowledge and poor or variable study designs, 
suggesting reevaluation of past studies may be warranted and could possibly shed light on a 
consensus that has previously eluded investigators. Here in this work we have shown that 
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vitamin C in the form of AA (administered as A2P), not DHA, preferentially increases 
intracellular vitamin C content; we have also demonstrated that supplementation with 
physiological concentrations of AA, that are achievable via oral supplementation, can decrease 
the malignant properties of vitamin C depleted human metastatic melanoma cells (Fig. 29). 
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Figure 29.  Possible before and after effects of AA supplementation in clinical patients. 
Individuals with cancer, including melanoma, are commonly found to have below normal levels 
of plasma AA. Our results in melanoma cells have demonstrated that physiological 
concentrations of AA decrease the protein accumulation and activity of HIF-1α and increase 
global DNA 5hmC content, likely resulting in demethylation of tumor suppressor gene 
promoters. Together, these factors decrease the malignant properties of metastatic melanoma 
cells, supporting the use of AA as a potential adjuvant anti-cancer therapy. 
 
Our evidence suggests reduction of malignant properties in these cells is likely attributed 
to the reestablishment of optimal activity of several cancer associated 2-OG dioxygenases, such 
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as the HIF hydroxylases and TET enzymes. We have also provided novel evidence that the HIF-
1 transcription factor can modulate the methylation of the genome by influencing the 
expression of TET2. It is our hope that these studies will inspire a closer look at past clinical AA 
investigations and further stimulate and support future inquiries into the clinical use of AA as an 
adjuvant anti-cancer therapy. 
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APPENDIX B: 
LIST OF ABBREVIATIONS 
 
2-OG:   2-oxoglutarate 
5caC:   5-carboxylcytosine 
5fC:   5-formylcytosine 
5hmC:  5-hydroxymethylcytosine 
5mC:   5-methylcytosine 
A2P:   Ascorbate 2-phosphate 
AA:   Ascorbic acid 
AML:   Acute myeloid leukemia 
BER:   Base excision repair 
BNIP3:  BCL2 Interacting Protein 3 
BRAF:  Murine sarcoma viral (v-raf) oncogene homolog B1 
BSA:   Bovine Serum albumin 
CaCl2:  Calcium chloride 
CBP:   CREB binding protein 
Ch:   Choline 
ChCl:   Choline chloride 
Clt:   Control 
CMML:  Chronic myelomonocytic leukemia 
CoCl2:  Cobalt chloride 
CO2:  Carbon dioxide 
Cont:   Control 
CpG:   Cytosine-phosphate-guanine 
C-TAD:  C-terminal transactivating domain 
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DHA:   Dehydroascorbic acid 
DKG:   Diketogulonic acid 
DNA:  Deoxyribonucleic acid 
DNMT:  DNA methyltransferases  
DSBH:  Double-stranded β-helix 
ECL:  Enhanced chemiluminescence 
EDHB:  Ethyl 3, 4-dihydroxbenozoate 
EDTA:  Ethylenediaminetetraacetic acid 
EGLN1: Prolyl hydroxylase 2 
EGLN2: Prolyl hydroxylase 1 
EGLN3: Prolyl hydroxylase 3 
EGTA:  Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
FBS:   Fetal Bovine Serum 
Fe:  Iron 
FH:  Fumarate hydratase 
Fig:  Figure 
FIH:   Factor Inhibiting HIF 
Glu:   Glucose 
GLUT:  Glucose transporter 
GULO:  L-gulonolactone oxidase 
HEMnLP:  Human Epidermal Melanocytes, neonatal, lightly pigmented 
HMGS: Human melanocyte growth supplement 
HIF:   Hypoxia Inducible Factor 
H2O2:  Hydrogen peroxide 
HRE:   Hypoxia response element 
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Hsp:   Heat shock protein 
IFN:   Interferon 
IL:   Interleukin 
IRB:  Institutional review board 
I.V.:   Intravenous 
KCl:  Potassium chloride  
Km:   The Michaelis constant 
MAPK: Mitogen-activated protein kinase 
MET:  Metastatic phase 
MgCl2: Magnesium chloride 
NAC:   N-acetyl cysteine 
NaCl:   Sodium Chloride 
NADPH:  Nicotinamide adenine dinucleotide 
ND:  Not detectable 
NF-κB:  Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NRAS: Neuroblastoma RAS viral oncogene homolog 
ns:  Not significant 
O2:  Molecular oxygen 
ODD:   Oxygen dependent death domain 
OPDA:  o-Phenylenediamine dihydrochloride 
PAGE:  Polyacrylamide gels 
PBS:   Phosphate buffer saline 
PBS-T:  Phosphate buffer saline-Tween 20 
PCR:  Polymerase chain reaction 
PHD:   Prolyl hydroxylase 
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PMT:   Photo-multiplier tube 
pVHL:  von Hippel-Lindau tumor suppressor protein 
qPCR:  Quantitative PCR 
RGP:  Radial growth phase 
RNA:  Ribonucleic acid 
ROS:   Reactive oxygen species 
RPMI:  Roswell park memorial institute medium 
RT:  Room temperature 
RT-PCR:  Reverse transcriptase-PCR 
SDH:  Succinate dehydrogenase 
SDS:   Sodium dodecyl sulfate 
SEM:   Standard error of mean 
siRNA: Small interfering RNA 
SSC:   Saline sodium citrate 
SVCT:  Sodium dependent vitamin C transporter 
TCA:   Tricarboxylic acid 
TDG:   Thymine-DNA glycosylase 
TEMPOL:  4-Hydroxy-2,2,6,6-tetramethyl-piperidinooxy 
TET:   Ten-eleven translocation enzyme 
Tris:   Tris(hydroxymethyl)aminomethane 
UHRF1: Ubiquitin-like PHD and RING finger domain-containing protein 1 
UV:  Ultraviolet 
VEGF:  Vascular endothelial growth factor 
VGP:  Vertical growth phase 
WGA:  Wheat germ agglutinin 
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β-gal:  β-galactosidase 
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